Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED]  
Document Date:  22-AUG-2019A Phase 1b, Open-label, Single-dose Study to Evaluate the 
Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric 
Subjects From Birth to Less Than [ADDRESS_964717]:   MK-7655A 1
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialTHIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION , NJ, U.S.A.
SPONSOR:
[COMPANY_006] Sharp & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc. 
(hereafter referred to as the Sponsor or [COMPANY_006])
One [COMPANY_006] Drive
P.O. Box [ADDRESS_964718] 
information can be found in the Investigator Trial File 
Binder (or equivalent) .
TITLE:
A Phase 1b, Open -label, Single -dose Study  to Evaluate the Pharmacokinetics, Safet y, and 
Tolerability  of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years ofAge 
With Confirmed or Suspected Gram- negative Infections
IND NUMBER: 108,[ADDRESS_964719] NUMBER:   2016-004328-[ADDRESS_964720]:   MK-7655A 2
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialTABLE OF CONTENTS
DOCUMENT HISTORY ....................................................................................................... 9
SUMMARY OF CHANGES ................................................................................................ 10
1.0 TRIAL SUMMARY .................................................................................................. 11
2.0 TRIAL DESIGN........................................................................................................ 11
Trial Design ........................................................................................................... 11
Trial Diagram ........................................................................................................ 13
3.0 OBJECTIVE(S) & HYPOTHESIS(ES) .................................................................. 15
Primary Objective(s) & Hypothesis(es) .............................................................. 15
Secondary Objective(s) & Hypothesis(es) ........................................................... 15
4.0 BACKGROUND & RATIONALE .......................................................................... 15
Background ........................................................................................................... 15
Pharmaceutical and Therapeutic Background .................................................... 15
Preclinical and Clinical Trials ............................................................................. 16
Preclinical Trials .......................................................................................... 16
Preclinical Juvenile Toxicity  Studies .................................................... 16
Phase 1 Clinical Trials ................................................................................. 16
Phase 2 Clinical Trials ................................................................................. 17
Phase 3 Clinical Trials ................................................................................. 18
Ongoing Clinical Trials ....................................................................................... 19
Imipenem/Cilastatin Clinical Experience in Pediatric Populations .................... [ADDRESS_964721] Population .................................... 19
Rationale for Dose Selection/Regimen/Modification ......................................... 21
Starting Dose for This Trial ......................................................................... 21
Maximum Dose/Exposure for This Trial ..................................................... 21
Rationale for Dose Interval and Trial Design .............................................. 21
Rationale for Endpoints ...................................................................................... 21
Pharmacokinetic/Pharmacody namic Endpoints ........................................... [ADDRESS_964722]:   MK-7655A 3
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Safety  Endpoints .......................................................................................... 22
Benefit/Risk ........................................................................................................... 23
5.0 METHODOLOGY ................................................................................................... 23
Entry Criteria ........................................................................................................ 23
Diagnosis/Condition for Entry  into the Trial ...................................................... [ADDRESS_964723] Exclusion Criteria .................................................................................. 25
Trial Treatment(s) ................................................................................................ 27
Dose Selection/Modification .............................................................................. 27
Dose Selection (Preparation) ....................................................................... 27
Dose Modification ....................................................................................... 28
Dose Modifications and Decisions After Interim Reviews .................. 29
Timing of Dose Administration .......................................................................... 31
Trial Blinding...................................................................................................... 31
Randomization or Treatment Allocation ............................................................ 31
Stratification .......................................................................................................... 31
Concomitant Medications/Vaccinations (Allowed & Prohibited) .................... 31
Rescue Medications & Supportiv e Care ............................................................. 32
Diet/Activity/Other Considerations ..................................................................... [ADDRESS_964724] Withdraw al/Discontinuation Criteria ................................................... [ADDRESS_964725] Replacement Strategy ............................................................................. 33
Beginning and End of the Trial ........................................................................... 33
Clinical Criteria for Early Trial Termination ................................................... 34
6.0 TRIAL FLOW CHART ........................................................................................... 35
7.0 TRIAL PROCEDURES ........................................................................................... 37
Trial Procedures ................................................................................................... 37
Administrative Procedures .................................................................................. 37
Informed Consent/Assent ............................................................................. 37
General Informed Consent/Assent ........................................................ [ADDRESS_964726]:   MK-7655A 4
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Inclusion/Exclusion Criteria ........................................................................ [ADDRESS_964727] .......................................................................... 38
Medical History ........................................................................................... 38
Prior and Concomitant Medications Re view ............................................... 38
Prior Medications .................................................................................. 38
Concomitant Medications ..................................................................... 38
Assignment of Screening Number ............................................................... 38
Assignment of Treatm ent/Randomization Number ..................................... 39
Trial Compliance ......................................................................................... 39
Clinical Procedures/Assessments ........................................................................ 39
Full and Directed Phy sical Examinations .................................................... 39
Height and Weight ....................................................................................... 39
Vital Sign Measurements ............................................................................. 40
Adverse Event Monitoring ........................................................................... 40
Local Tolerability  Monitoring ..................................................................... 40
Laboratory  Procedures/Assessments .................................................................. 40
Laboratory  Safety Evaluations (Hematology , Chemist ry, and 
Urinaly sis).................................................................................................... 40
Pharmacokinetic/Pharmacody namic Evaluations ........................................ 41
Blood Collection for Plasma MK- 7655A ............................................. 42
Other Procedures ................................................................................................ .43
Withdrawal/Discontinuation ........................................................................ [ADDRESS_964728] Blinding/Unblinding ....................................................................... [ADDRESS_964729]:   MK-7655A 5
Protocol/Amendment No.: 020-[ADDRESS_964730] ............................................................................ 47
Evaluating Adverse Events ................................................................................. 47
Sponsor Responsibility  for Reporting Adverse Events ...................................... 50
8.0 STATISTICAL ANALYSIS PLAN ........................................................................ 50
Statistical Analysis Plan Summary ..................................................................... 50
Responsibility for Analyses/In -House Blinding ................................................. 51
Hypotheses/Estimation ......................................................................................... 52
Analysis Endpoints ............................................................................................... 52
Pharmacokinetic/Pharmacody namic Endpoints .................................................. 52
Safety  Endpoints ................................................................................................ .52
Analysis Populations ............................................................................................. 52
Pharmacokinetics Population .............................................................................. 52
Safety Anal ysis Populations ............................................................................... 53
Statistical Methods ................................................................................................ 53
Modeling & Simulation Methods for Pharmacokinetic Anal yses...................... [ADDRESS_964731]/Destruction/Returns and Reconciliation .............................................. [ADDRESS_964732]:   MK-7655A 6
Protocol/Amendment No.: 020-[ADDRESS_964733] Records ..................................................................... 56
Confidentiality  of Investigator Information ........................................................ 57
Confidentiality  of IRB/IEC I nformation ............................................................. [ADDRESS_964734] for Clinical Trials ........................................................ 64
Approximate Blood/Tissue Volumes Drawn/Collected by [CONTACT_26347] ................................................................................................... [ADDRESS_964735] of Abbreviations ............................................................................................ 68
13.0 SIGNATURES ........................................................................................................... 70
Sponsor's Representative ..................................................................................... [ADDRESS_964736]:   MK-7655A 7
Protocol/Amendment No.: 020-[ADDRESS_964737] OF TABLES
    
Table 1 Trial Treatment ....................................................................................................... 27
Table 
2Imipenem/Cilastatin/Relebactam (IMI/REL) Doses by  [CONTACT_50799] ...................... [ADDRESS_964738]:   MK-7655A 8
Protocol/Amendment No.: 020-[ADDRESS_964739]:   MK-7655A 9
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialDOCUMENT HISTORY
Document Date of Issue Overall Rationale
MK-7655A-020 -00 15-NOV -2016 Original Protocol
MK-7655A-020 -01 11-JAN- 2019 Amendment 1 (Global)
Primary  reasons for the amendment:
Allow enrollment of subjects who may have neonatal 
hyperbilirubinemia within 24 hours of birth that is part of a 
normal phy siologic process.
Remove weight -based exclusion criterion for Cohorts 4 and 5.
MK-7655A-020 -02 22-AUG -2019 Amendment 2 (Global)
Primary  reason for the amendment:
Allow enrollment into Cohort [ADDRESS_964740]:   MK-7655A 10
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON(S) FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
5.1.[ADDRESS_964741] I nclusion Criteria Inclusion Criterion #4: Revised 
to allow enrollment into 
Cohort [ADDRESS_964742] 37 weeks.
ADDITIONAL CHANGE (S)FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
2.1
2.2
[IP_ADDRESS]
[IP_ADDRESS]
[IP_ADDRESS].1
5.2.2
8.7Trial Design
Trial Diagram
Starting Dose for This Trial
Dose Selection (Preparation)
Dose Modifications and 
Decisions After Interim 
Reviews
Timing of Dose Administration
Interim Review sfor Potential 
Dose AdjustmentUpdated text to reflect
a)completion of Cohort 4 
interim review and resulting 
dose modifications, as 
previously  communicated via 
Protocol Clarification Letter, 
and b)completion of 
enrollment into Cohort
4.Revised to incorporate 
summary  o f dose 
modifications implemented 
after the interim review after 
50% en rollment in Cohort 4. 
  059MV0
Product:   MK-7655A 11
Protocol/Amendment No.: 020-[ADDRESS_964743] Identifiers MK-7655A ( imipenem/cilastatin/relebactam [IMI/REL] )
Generic Name: N/A
Trial Phase Phase 1b
Clinical Indication Treatment of bacterial infection sin pediatric population s
Trial Type Interventional
Type of control No treatment control
Route of administration Intravenous
Trial Blinding Unblinded Open -label
Treatment Groups MK-7655A (IMI/REL)
Number of trial subjects Approx imately 44subjects w ill be enrolled.
Estimated duration of trial The S ponsor estimates that the trial will require approximately 3years
from the time the first subject signs the informed consent /assent until 
the last subject’s last study -related phone call or visit.
Duration of Participation Each subject will participate in the trial for up to [ADDRESS_964744] ’sparent or legally acceptable representative signs the 
informed consent /assent form through the final contact. After a 
screening phase of up to 2days, each subject will receive 1dose of 
IMI/REL . After the single dose, each subject will be follow ed for 
14(+2) days for adverse events .
A list of abbreviations used in this docum ent can be found in Section 12.4 –List of 
Abbreviations .
2.0TRIAL DESIGN
Trial Design
This is an open -label, noncomparative study  of a single intravenous (IV)dose of MK-7655A
(a fixed -dose combination of imipenem/cilastatin/relebactam, hereafter referred to as 
IMI/REL) in male and female pediatric subjects from birth to less than [ADDRESS_964745] -of-care antibacterial therapy  for treatment of a confirmed or suspected 
Gram -negative bacterial infection.
A minimum of 44subjects will be enrolled, each into 1of the following 5pediatric age 
cohorts:
Cohort 1: Adolescents ( age 12 to <18 y ears); at least 6 subjects
Cohort 2: Older children (6 to <12 years) ; at least 6 subjects
Cohort 3: Younger c hildren (2 to < 6 years) ; at least 6 subjects
Cohort 4: Infants and toddlers (3 months to <2 years) ; at least 8subjects , at least 4 of 
whom are <1year of age 
  059MV0
Product:   MK-7655A 12
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialCohort 5: Neonates and young infants (birth to <3 months) ; at least 18subjects, who 
will be further divided into the following age subcohorts :
o4 weeks to < 3 months of age ; at least 6 subjects
o1 to <4 weeks of age ; at least 6 subjects
o<1 week of age; at least 6 subjects
All subjects will receive a single dose of IMI/REL administered via IV infusion at the doses
specified in Table 2of Section 5.2 – Trial Treatments .
The initial dose for Cohorts 1, 2, and 3 
was IMI/REL 15/7.5 mg/kg , and single IV doses for all cohorts didnot exceed the adult 
maximum dose of 500 mg IMI and 250 mg REL.The study  design is depi[INVESTIGATOR_98864] a trial 
diagram 
in Section 2.2 – Trial Diagram .
For Cohorts 1, 2, and 3, enrollment was initiated in parallel, and an interim review was 
conducted in each age cohort after the first 3(50%) subjects were enrolled , at which point, 
enrollment in that cohort was pause d.
Enrollment in each cohort would continue past the third subject without dose modification 
until all 6 subjects were enrolled in Cohorts 1, 2, and 3 ifthe following occur red:
1. T he interim reviewdemonstrate dthat the selected initial dose was suitable based on 
pharmacokinetic (PK)target attainment that was similar to that in adults for a given
age cohort (details in Section [IP_ADDRESS] – Dose Modification ), and
2.
The dose demonstrate dan acceptable safet y profile in the exposed cohort , as 
described in Section [IP_ADDRESS] –Dose Modification .
Alternativel y, enrollment in each cohort would continue with a dose modification based on 
Section [IP_ADDRESS] ifthe following occur red:
1. The interim review reveal ed a suboptimal (ie, too high or too low) initial dose based
on inadequate (ie, too high or too low) PKtarget attainment relative to adults for a 
given age cohort (details in Section [IP_ADDRESS] – Dose Modification ), or
2.
The safet y profile was not acceptable .
Dose modifications following the interim reviews in Cohorts 1 through 3 are described in 
Section [IP_ADDRESS].1.
When enrollment of all 6subjects each in Cohorts 1, 2, and 3 was completed, a second
interim review was performed in which aggregated data from Cohorts 1, 2, and 3 wasused to 
(1) develop and refine a pediatric population PK model andconduct simulations to evaluate 
PKtarget attainment ,and (2) assess whether the safet y profile was acceptable for each age 
cohort . The findings from the s econd interim review were used to inform the proposed initial 
doses for Cohorts 4 and 5, which is 10/5mg/kgIMI/REL . Subject enrollment of Cohorts [ADDRESS_964746] 
4(50%) subjects are enrolled in Cohort [ADDRESS_964747] 9 (50%) subjects are enrolled in 
Cohort 5 (regardless of subcohort) , at which point, enrollment in that cohort will pause .
Enrollment will continu e past the fourth subject in Cohort [ADDRESS_964748] in Cohort 5 
without dose modification if the following occurs : 
  059MV0
Product:   MK-7655A 13
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential1.The interim review demonstrates that the selected initial dose is suitable based on PK
target attainment that is similar to that in adults for a given age cohort (details in 
Section [IP_ADDRESS] –Dose Modification), and
2.The dose demonstrates an acceptable safet y profile in the exposed cohort, as 
described in Section [IP_ADDRESS] –Dose Modification.
Alternativel y, enrollment in each cohort will continue with a dose modification based on 
Section [IP_ADDRESS] –Dose Modification ifthe following occurs :
1.The interim review reveals a suboptimal (too high or too low) initial dose based on 
inadequate (too high or too low) PKtarget attainment relative to adults for a given 
age cohort (details in Section [IP_ADDRESS] –Dose Modification) , or
2.The safet y profile is not acceptable.
When enrollment into Cohort s4 and 5 has been completed, a final analysis of PK and safet y 
data will be performed with aggregated data from Cohorts 1 through 5to refine the optimal 
dosing for pediatric subjects based on PK target attainment and an acceptable safet y profile .
At the time of this protocol amendment (-02), enrollment into Cohort 4 has been completed. 
Dose modifications following the interim review (ie, after achieving 50% enrollment) in 
Cohort 4are described in Section [IP_ADDRESS].1.
Any dose modifications for Cohort 5 will be selected and communicated as described in 
Section [IP_ADDRESS] –Dose Modification and will not exceed the single IV dosage of IMI/REL 
500/[ADDRESS_964749], PK parameters will be assessed for up to 6 hours and safety  parameters will 
be assessed for up to 24 hours following the single IV dose of IMI/REL. Subjects will have a 
safet y follow -up visit or telephone contact 14(+2) day s after the infusion.
Each subject will participate in the trial for up to [ADDRESS_964750]’s parent 
or legally  acceptable representative (LAR) signs the informed consent form through the final 
contact. This includes a screening phase of up to 2 days before receiving a single dose of 
IMI/REL, and then a follow -up period of 14 (+2) day s.
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit window s, are outlined in the Trial Flow Chart -Section 6.0. Details of each 
procedure are provided in Section 7 .0–Trial Procedures.
Trial Diagram
The trial design is depi[INVESTIGATOR_6517] 1. 
  059MV0
Product:   MK-7655A 14
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialFigure 1Schematic of Study  Design for Study  MK -7655A -020
Abbreviations: IMI/REL: imipenem/cilastatin/relebactam; mos: months; PK: pharmacokinetic; TBD: to be 
determined; yrs: years
a.Will not exceed a single IV dose of IMI/REL 500/250 mg.
b.The criteria for PK and safety target achievement are described in Section [IP_ADDRESS] –Dose Modification. 
c.New  doses of IMI/REL will be selected and communicated as described in Section [IP_ADDRESS] –Dose 
Modificati on and will not exceed the single IV dosage of IMI/REL 500/250 mg. Dose modifications and 
decisions following the interim reviews in Cohorts 1 through 4are described in Section [IP_ADDRESS].1.
 
  059MV0
Product:   MK-7655A 15
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential3.0OBJECTIVE(S) & HYPOT HESIS(ES)
Primary Objective(s) & Hypothesis (es)
Objective: To obtain plasma PKdata and characterize the PK profile of imipenem, 
cilastatin ,and relebactam (REL) following administration of a single IV dose of IMI/REL in 
pediatric subjects from birth to less than [ADDRESS_964751] -of-care 
antibacterial therapy  for a confirmed or suspected Gram -negative bacterial infection .
Hypothesis: No formal hy pothesis testing will be performed for this objective.
Secondary Objective(s) & Hyp othesis(es)
Objective:  To evaluate the safet y and tolerability profile of a single IVdose of IMI/REL in 
pediatric subjects from birth to less than [ADDRESS_964752] -of-care 
antibacterial therapy  for a confirmed or suspected Gram -negative bacterial infection.
4.0BACKGROUND & RATIONA LE
Background
Refer to the Investigator’s Brochure (IB) for detailed background information on MK-
7655A .
Pharmaceutical and Therapeutic Background
MK-7655 (relebactam, referred to as REL ) is a parenteral (IV), small -molecule β-lactamase 
inhibitor (BLI) , which is being developed as a fixed -dose combination in a single vial with 
imipenem/cilastatin (referred to as IMI) for the treatment of infections caused by 
[CONTACT_6907] -negative bacteria. Throughout this document ,the fixed -dose combination of 
imipenem/cilastatin/relebactam (MK -7655A) is referred to as IMI/REL.
β-lactam antibiotics (penicillins, cephalosporins, carbapenems, and monobactams) are among 
the most frequently used antimicrobial agents in clinical practice. The unrelenting 
development of resistance to these β-lactam antibiotics by [CONTACT_587148] β-lactamases is 
the most important resistance mechanism among Gram -negative bacteria and poses an 
ongoing threat to the clinical utility  of all β-lactams. Therefore, there is an urgent need for 
new BLIs that can be combined with existing β-lactam antibiotics to protect against 
hydrolysis by  1 or more of the 4 classes (A, B, C and D) of β -lactamase enzy mes.
Relebactam represents a new generation of BLIs to combat evolving clinical resistance and 
to maintain the usefulness of the β-lactam class of antibiotics. Relebactam is an inhibitor of 
Ambler c lass A and c lass C BLI s. This BLI has sub- micromolar potency  for AmpC, a class C 
β-lactamase responsible for resistance in a majority  of imipenem -resistant Pseudomonas 
aeruginosa. In addition, REL  is active against the class A KPC β-lactamase present in some 
Enterobacteriaceae, including Klebsiella strains, as well as against many other class A and C 
β-lactamases. Relebactam has no activity  against the class B metallo -β-lactamases (including  
  059MV0
Product:   MK-7655A 16
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialNDM -1, IMP, or VIM-containing strains) or class D β-lactamases (including 
OXA- producing strains).
Preclinical and Clinical Trials
Preclinical Trials
Preclinical data, including in vitro microbiological studies with imipenem -resistant clinical 
isolates of P. aeruginosa and KPC -producing organisms, as well as in vivo infection models 
with imipenem -resistant P. aeruginosa and K. pneumoniae , suggest that REL, in combination 
with IMI, has the potential to fulfill a significant and growing medical need by [CONTACT_1541] a 
next- generation BLI to combat severe Gram -negative bacterial infections. Preclinical toxicity  
studies in rats and monkey s have demonstrated that REL is generall y well tolerated. There 
was no evidence of adverse effects of REL as a single agent on cardiovascular, central 
nervous system, and respi[INVESTIGATOR_709629]-characterized preclinical safet y 
pharmacology  models. In monkey s, reversible renal tubular degeneration was seen in 
monkey s at 7-fold the therapeutic exposure at 250 mg every  6hours ; however, no evidence 
of renal tubular epi[INVESTIGATOR_709630] 
3Xthe clinical exposure after 3months of repeated dosing. Combination studies conducted 
in monkey s demonstrate that dosing with REL and IMI at 1Xthe projected therapeutic 
exposure was well tolerated, and antemortem and postmortem findings were similar to 
monkey s treated with IMI alone, demonstrating that toxicity  is not exacerbated by [CONTACT_709636]. I n addition, no evidence of renal toxicity  has been obs erved in clinical studies.
Preclinical Juvenile Toxicity Stud ies
Results from preclinical juvenile toxicity  studiesin rats have demonstrated that the 
no-observed -effect level for REL in juvenile rats was ≥450mg/kg/day. Relebactam was 
administered to rats subcutaneousl y (postnatal day 14 to 34) or intravenously  (postnatal 
day35 to 56/57) once daily at doses of 0, 65, 200, or 450mg/kg/day  from postnatal week 3 
through postnatal week 9. There were no REL -related findings up to the maximum feasible 
dose of 450mg/kg/day . Histomorphologic findings related to repeated IVadministration 
were present at comparable incidences between control and REL -treated animals.
Phase 1Clinical Trials
To date, REL  has been evaluated in approximately  [ADDRESS_964753] 1dose of REL  across 7completed Phase 1studies (PN001, PN002, PN005, PN007, 
PN009, PN012, and PN019 ). Health y young and elderl y adults of both sexes and adults of
varying degrees of renal insufficiency  have been studi ed, including patients with end-stage 
renal disease on hemodialy sis.
Unblinded safet y data from the Phase 1studies have demonstrated that single and multiple 
IVdoses of REL  have been generally  safe and well tolerated throughout the dose ranges 
tested and across the various subject populations. In PN009 (a standard thorough QTc study  
evaluating the effect of REL  on the QTc interval), a supratherapeutic dose of RE L did not 
prolong the QTc interval to a clinicall y meaningful extent and no risk of cardiac 
repolarization prolongation was identified. 
  059MV0
Product:   MK-7655A 17
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialIn PN001, cases of mild elevations in hepatic transaminases above the upper limit of normal 
range (ULN) were observed inthe multiple -dose treatment arms in which REL was 
coadministered with IMI. Elevations were also seen at similar frequencies in subjects 
receiving IMI alone. None of the liver transaminase elevations in these subjects were 
associated with clinical manifest ations. The elevations were not dose-related and were 
reversible after discontinuation of dosing. Generally  mild elevations in hepatic transaminases 
were also observed in Japanese subjects receiving multiple doses of REL in PN012. Similar 
to observations in PN001, the increases in alanine aminotransferase (ALT)/aspartate 
aminotransferase (AST) resolved after completion of dosing. Elevations have not been 
observed in subjects administered single or multiple doses in PN002, PN005, PN007, or 
single doses in PN009.
Pharmacokinetic data from Phase 1 studies demonstrate the following:
REL  exposures increase proportionall y with dose ;doses at 125 mg and above 
adequatel y achieved and exceeded the identified REL PK target of area under the 
concentration time curve ( AUC 0-∞) ≥37.5 μM-hr.
For all age and gender comparisons, the 90% confidence intervals for the geometric 
mean ratios of AUC 0-∞for REL , imipenem, and cilastatin fell completely within the 
(0.50 to 2.00) target interval. Therefore, no dose adjustments are recommended based 
on age or gender.
PK profiles of REL, imipenem, and cilastatin in healthy  Japanese subjects were 
similar to historical data obtained from non -Japanese subjects.
PK data from a study  ofrenal -impaired subjects (PN005
)were consistent with 
expectations given that REL , imipenem, and cilastatin are cleared almost entirely 
renall y in healthy  subjects. Plasma clearance, terminal half-life (t1/2)
,and AUC 0-∞
were significantly  and similarly  altered for each of these 3 analytes when comparing 
subjects with renal impairment to their health y matched control subjects.
REL  and imipenem penetrate to a similar extent into the extracellular (epi[INVESTIGATOR_709631]) 
of the lung.
Supratherapeutic levels of REL  had no impact on population -specific QTc.
REL  has low potential for an y clinicall y meaningful drug -drug interaction s.
Phase 2Clinical Trials
To date, coadministration of IMI and REL has been evaluated in 2 Phase 2 randomized, 
double -blind, multicenter, comparative studies evaluating the safet y, tolerability , and efficacy 
of IMI +REL versus IMI alone in adults with complicated intra-abdominal infection (cIAI) 
(PN004; 351subjects total) and in adults with complic ated urinary  tract infection (cUTI) 
including pyelonephritis (PN003; 302subjects total). In each study , subjects were 
randomized in a 1:1:1 ratio to 1 of 3 treatment groups :(1) IMI + REL  (250 mg), 
(2)IMI +REL  (125 mg), or (3) IMI + placebo (to REL ).
The primary  efficacy  analysis for each study  indicates that treatment with either 250mg or 
125mg of IMI+ REL is at least as effective as IMI alone as measured by [CONTACT_709637]  
  059MV0
Product:   MK-7655A 18
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidentialsubjects with favorable clinical (PN004) or microbiological (PN003) response at 
discontinuation of IV study therap y. Specifically , in PN004, the proportion of subjects in the 
primary  analysis population with a favorable clinical response was 96.3% (78/81) in subjects 
who received IMI+ REL (250 mg), 98.8% (85/86) in subjec ts who received IMI+ REL 
(125 mg), and 95.2% (79/83) in subjects who received IMI + placebo. In PN003, the 
proportion of subjects in the primary  analysis population with a favorable microbiological 
response was 95.5% (64/67) in subjects who received IMI +REL (250 mg), 98.6% (70/71) in 
subjects who received IMI + REL (125 mg), and 98.7% (74/75) in subjects who received 
IMI+ placebo.
The incidence rate of adverse experiences observed in subjects in studies PN004 and PN003 
who received either dose of IMI+ REL (either the 125 mg or the 250 mg dose of REL) was 
generall y comparable to that observed in subjects who received IMI + placebo. No evidence 
of significant renal toxicity  or hepatotoxicity  was observed. Given the mild elevations in 
hepatic transaminases observed inPN001 (Section [IP_ADDRESS]) , close monitoring for 
transaminase elevations was included in PN004 and PN003. As part of this monitoring, the 
following [ADDRESS_964754] (ECI s) triggered staged evaluation and 
monitoring of subjects with these elevations: (1) confirmed AST or ALT ≥5× ULN ,and (2) 
ALT or AST ≥3× ULN and total bilirubin ≥2×ULN and, at the same time, alkaline 
phosphatase <2 × ULN. These ECIs were experienced by a small number of subjects in each 
study  (no more than 2subjects in a given treatment group per study ), and in both studies, 
there were no statistically  significant differences in the percentage of subjects meeting the 
definition of either ECI between either of the 2 IMI + REL groups versus the IMI + placebo 
group.
Phase 3 Clinical Trials
One completed pi[INVESTIGATOR_9205] 3 study  (PN013) evaluated the safety  and efficacy  of the fixed -
dose combination IMI/REL  versus comparator (colistin [in the form of colistimethate 
sodium, CMS] + IMI) in 50subjects with hospi[INVESTIGATOR_307]-acquired or ventilator -associated bacterial 
pneumonia (HABP/VABP ), cIAI, or cUTI caused by [CONTACT_709638] -nonsusceptible Gram-
negative bacterial infections.  
In PN013, IMI/REL was at least as efficacious as CMS + IMI, as supported by [CONTACT_709639]:
The primary  efficacy  endpoint of favorable overall response was achieved by a 
comparable percentage of subjects who received IMI/REL and CMS + IMI.
Favorable clinical response was achieved by a higher percentage of subjects who 
received IMI/REL than subjects who received CMS + I MI at all time points assessed.
All-cause mortality  was experienced by a  lower percentage of subjects who received 
IMI/REL than subjects who received CMS + IMI.
In addition, results from PN013 demonstrated that treatment with IMI/REL was well 
tolerated in criticall y ill subjects and had a more favorable safet y profile than treatment with 
CMS + IMI. In addition, treatment with IMI/REL exhibited a more favorable renal safety 
profile than treatment with CMS + IMI, as demonstrated by a lower incidence of  
  059MV0
Product:   MK-7655A 19
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidentialtreatment -emergent nephrotoxicity  (a reported side effect of colistin) in subjects who 
received IMI/REL.
Ongoing Clinical Trials
The following studies in adults are currentl y ongoing:
Two Phase 3 studies to evaluate the safet y and efficacy  of IMI/REL compared with 
that of pi[INVESTIGATOR_049]/tazobactam in adult subjects with HABP/VABP (Protocol 014 
[PN014], which was initiated in early 2016 [first subject enrolled 28-JAN-2016], and 
Protocol 016 [PN016], which was initiated in 2018 [first subject enrolled 18-SEP-
2018] . PN016 is being conducted to support IMI/REL registration in China).
A Phase 3 study  to evaluate the safety  and efficacy  of IMI/REL in Japanese adult 
subjects with cIAI or cUTI (Protocol 017 [PN017], which was initiated in late 2017 
[first subject enrolled 04-OCT -2017]). As of January  2019, enrollment was complete, 
but the final C linical Study Report was not available.
Imipenem/Cilastatin Clinical Experience in Pediatric Populations
There has been considerable experience with the use of IMI in both adults and pediatric 
patients since its initial approval over 30 years ago. Imipenem/cilastatin is curre ntly 
registered and approved in [ADDRESS_964755] been treated with IMI.To date, approximately  2,332 patients (including 
223pediatric subjects) have been exposed to IMI alone or as part of an active comparator 
regimen in clinical trials conducted by [CONTACT_1034]. The [ADDRESS_964756] infections . Imipenem/cilastatin was efficacious 
and generally well tolerated in both studies.
Rationale
Rationale for the Trial and Selected Subject Population
This is the first study  in support of the pediatric development of IMI/REL for the treatment of 
bacterial infections caused by [CONTACT_6907]-negative bacteria , including HABP, VABP, cUTI, and 
cIAI. Overall, the pathogenesis, microbiology , and treatment of these diseases are similar in 
pediatric patients and in adults.
Increasingl y, multidrug resistant (MDR) Gram -negative bacteria, especiall y extended 
spectrum β-lactamase -producing organisms and carbapenem -resistant organisms, are 
becoming a worldwide problem in both adult as well as pediatric patients .Multidrug 
resistance severel y limits the utility  of currently  available antibacterials. Although new and 
effective antibacterials have been introduced to combat MDR Gram -positive organisms, 
clinicians have been forced to utilize older drugs with known limitations in the treatment of 
resistant Gram -negative pathogens, most notably  those with carbapenem resistance. Due to 
the absence of effective and tolerable antibacterials, infections caused by 
[CONTACT_222295] -resistant Gram -negative organisms have a high mortality  rate. Even with  
  059MV0
Product:   MK-7655A 20
Protocol/Amendment No.: 020-[ADDRESS_964757] pathogens, including carbapenem -resistant pathogens, range from 16% up to as 
high as 60% [ 1, 2, 3, 4, 5 ].
As with adults, infections caused by 
[CONTACT_709640] β-lactamase -producing organisms in 
pediatric patients are associated with longer hospi[INVESTIGATOR_7959], frequent complications, and 
increased mortality , at higher than adult rates in certain regions [6, 7, 8]. Pediatric patients 
are particularly  vulnerable toMDR Gram -negative pathogens due to lack of broad -spectrum 
antibiotics approved for use in pediatric patients. For treatment of carbapenem -resistant 
Enterobacteriaceae infections in pediatri c patients, there are few treatment alternatives, such 
as aminogly coside monotherap y, fluoroquinolones, trimethoprim
-sulfamethoxazole ,
fosfomy cin, and nitrofurantoin (mostly  for treatment of uncomplicated urinary  tract 
infection ). Many of these antibiotics have limitations, such as the rapid emergence of 
resistance when aminogly cosides are used as single agents for bacteremia and the caution 
that needs to be exercised when prescribing fluoroquinolones to pediatric patients owing to 
osteoarticular side -effec ts observed in animal models [9].
As 
treatment options are limited for MDR infections, and given that there are fewer 
antibiotics approved for use in pediatric patients as well as the dearth of clinical trials 
conducted in pediatric patients, the problem is even more critically  important to address [9]. 
Carbapenems are the mainstay  of treatment of MDR Gram -negative infections ; therefore, the 
emergence of carbapenem -resistant organisms in recent years is particularly  worrisome [
10].
The addition of REL  to IMI to restore IM
I susceptibility for pathogens that produce class A 
and C β-lactamases therefore addresses an area of growing unmet medical need . 
Furthermore, IMI/REL is unique among β-lactam/BLI  combinations in development due to 
the long history  of pediat ric safet y and efficacy  (Section 4.1.4 – Imipenem/Cilastatin Clinical 
Experience in Pediatric Populations ) and the broad spectrum of activity  of the β-lactam 
compound.
The current [LOCATION_002] (US) Food and Drug Administration guidance document for 
pediat ric PK studies focuses on appropriate dosing in the pediatric population based on PK 
data [11]. The PK of a drug in the pediatric population usually  cannot be precisel ypredicted 
from PK or clinical studies ofadult subjects ;rather, specific PK studies in pediatric subjects 
are needed to determine appropriate pediatric dosing. Thus, the current study  willbe 
conducted to investigate the PK and safety  of a single IV dose of IMI/REL in pediatric 
subjects from birth to <[ADDRESS_964758] age cohort, 
in accordance with guidance from the Food and Drug Administration and the European 
Medicines Agency  (EMA ). The information from this study  will be used to determine 
appropriate dosing regimens for a subsequent efficacy  study of IMI/REL  in a pediatric 
population. 
  059MV0
Product:   MK-7655A 21
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Rationale for Dose Selection/Regim en/Modification
Starting Dose for This Trial
The initial dose of IMIfor pediatric subjects in Cohorts 1 through 3 in this study  was 
15 mg/kg, as designated in the current I MI label (PRI MAXIN ®and TIENAM ®). The dosing 
ratio of 2:1 for IMI:REL that isused in adult Phase 2 and 3 trials is used in the current trial. 
Thus, the initial dose of REL for pediatric subjects in Cohorts 1 through 3 was 7.5mg/kg. 
The initial doses were modified (maintaining the 2:1 IMI:REL dosing ratio) based on interim 
reviews in each age cohort , per the criteria described in Section [IP_ADDRESS] –Dose Modification .
The dose modifications for Cohorts 1 through 3 are described in Section [IP_ADDRESS].1.
The initial dose ofIMI/REL  for pediatric subjects in Cohorts 4and 5 wasselected based on 
updated PKmodeling and simulation analy ses, after incorporating observed PK data from 
Cohorts 1 through 3 during the second interim review (Section [IP_ADDRESS].1) .For Cohort 4, the 
initial dose of 10/5 mg/kg was modified based on the interim review as described in 
Section [IP_ADDRESS].1. For Cohort 5, the initial dose of 10/5 mg/kg may later be modified 
(maintaining the 2:1 IMI:REL  dosing ratio) based on subsequent interim review s in thatage 
cohort.
Maximum Dose/Exposure for This Trial
As descr ibed in Section [IP_ADDRESS] –Dose Modification , the doses for each age cohort in this 
study may be modified based onresults of observed PK data from interim review s.The final 
pediatric doses will not exceed the dosage currently  under study  for adult subjects in 
2separate P hase 3 trials (ie, maximum single IV dos eof IMI/REL 500/ 250mg).
Rationale for Dose Interval and Trial Design
A single IVdose of IMI/REL  will be administered to each subject in this study . A 
single -dose rather than amultiple -dose study  design was selected from the observed PK 
properties of IMI/REL in adults. A short half-life (approximately  30 to 60minutes) of both 
imipenem and REL and lack of accumulation of any drug components was obse rved in adult 
studies; these properties are expected to be the same in pediatric subjects.
Rationale for Endpoints
Pharmacokinetic /Pharmacodynamic Endp oints
Based on established literature in the field and data from the adult development program, 
efficacy  of IMI/REL  is driven by  [CONTACT_709641] 
(TMI C)within the dosing interval for imipenem and by [CONTACT_709642] (as measured by 
[CONTACT_12265]) for REL . Because the pathogenesis and microbiology  of the infections for which 
IMI/REL is being developed are similar in adult and pediatric populations , the PKtargets 
selected in this trial are the same as those for adults. For REL , exposure isthe metric of 
interest, w ith a target of AUC 0-∞≥37.5 μM-hr(and ≤200 μM-hr) after single -dose IV 
administration of IMI/REL . For imipenem, the target isfor subje cts to have T
MIC of≥30%
for relevant minimum inhibitory  concentrations of interest (and AUC 0-∞≤250 μM-hr). Doses  
  059MV0
Product:   MK-7655A 22
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidentialof IMI/REL associated with this exposure and TMIC have been established as being safe and 
efficacious in adults.
Plasma concentrations of REL , imipenem , and cilastatin will be determined. The REL and 
imipenem data will be used to develop a pediatric population PK model, using the adult 
model as a starting point ; the model will then be used in simulations to determine suitable 
dosing regimen sfor subsequent and separate pediatric clinical efficacy  trials . The PK 
properties of cilastatin based on data from this trial will also be described.
Rationale for PK S ampl ing Scheme
Pharmacokinetic sampling will be conducted in each age cohort , taking into consideration the
likely minimum body  weight of each age cohort and recommended limits on pediatric blood 
sampling .
Four PK samples per subject will be collected in each of the age cohorts as follows :
1.First PK sample: predose sample taken within 30minutes before the start of study 
drug infusion.
2.Second PK sample :collected within 10minutes after the end of study  drug infusion.
3.Third PK sample:
Cohorts 1through 4: obtained 1.5 to 2.5 hours after the start of study  drug
infusion.
Cohort 5: obtained 2 to 5 hours after the start of study drug infusion.
4.Fourth PK sample:
Cohorts 1through 4: obtained 4.5to 6 hours after the start of study  drug 
infusion.
Cohort 5: obtained [ADDRESS_964759] PK sample establishes a baseline andwill allow for 
evaluation of bioanal ytical interference (ie,to ensure there is no analy te of interest detected 
before dosing) . The second PK sample will be used to determine the maximum observed 
plasma concentration (Cmax). The third and fourth PK sample s will provide data during the 
elimination phase of the study  drug and thus, will allow characterizat ion of the selected PK
parameters , AUC 0-∞and TMIC. For Cohort 5, a full PK profile is anticipated by [CONTACT_5638] 
6hours; however, sampling out to [ADDRESS_964760]:   MK-7655A 23
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Benefit/Risk
In this trial, subjects will receive a single IV infusion of IMI/REL in addition to 
standard- of-care treatment. Nodirect or immediate clinical benefit is anticipated from 
participation in this single -dose PK study .While no direct clinical benefit to participants is 
anticipated, the risks of administration of a single dose of IMI/REL  are considered to be 
minimal. Imipenem /cilastatin has a well- established safet y and tolerability  profile among 
pediatric patients , both from the pediatric development program and from decades of clinical 
use for serious bacterial infections (see more in Section 4.1.4 –Imipenem/Cilastatin Clinical 
Experience in Pediatric Populations ).Furthermore, there are no significant or excessive 
adverse effects observed among other clinical studies involving IMI/REL to date (see more 
in Section 4.1.2 –Preclinical and Clinical Trials and Section 4.1.3 –Ongoing Clinical 
Trials).
Obtaining blood sample sfor PK analysis does pose a small risk, which isminimized by 
[CONTACT_709643] .Although 
more frequent , the proposed study  procedures described in Section 6.0–Trial Flow Chart are 
general ly standard procedures performed for the target patient population (eg, chemistry  and 
hematology  measurements) . One study  visit is scheduled 14days after study  drug infusion 
and therefore will occur generall y when the subject is no longer expected to be hospi[INVESTIGATOR_057] ; 
this visit can be conducted in person at the study site or by  [CONTACT_756], and only  a concomitant 
medication review and AE monitoring will be conducted .
The procedures required for this protocol are necessary  to support thorough evaluation of the 
PK and safet yprofile of the study  drug. A thorough assessment of PK and safet y in this stud y 
will support determination of adequate and safe dosing for evaluation of efficacy of treatment 
in subsequent confirmatory trial(s) , thus ensuring an ethicall y sound treatment regimen that 
will minimize potential for treatment failure in this vulnerable population .As such, data from 
this study  present a future opportunity to support availability  of IMI/REL to pediatric patients
with unmet medical need.
Notably , subjects are required to be concomitantly  receiving or to have recentl y completed 
(within 48 hours prior to study  drug administration) standard- of-care antibacterial treatment 
for their confirmed or suspected underl ying infection. No reliance is placed on the single 
dose of IMI/REL to provide efficacious treatment.
Additional details regarding specific benefits and risks for subjects participating in this 
clinical trial may  be found in the accompan ying IB and informed c onsent documents.
5.0METHODOLOGY
Entry Cr iteria
Diagnosis/Condition for Entry into the Trial
Male and female subjects from birth to <[ADDRESS_964761]:   MK-7655A 24
Protocol/Amendment No.: 020-[ADDRESS_964762]:
1.Have a parent or LAR who provides written informed consent for the trial on the 
subject’s behalf after understanding the study procedures, alternative treatments 
available, and risks involved with the study , and voluntarily  agrees to allow the 
subject to participate. Assent is to be obtained from minors as applicable according to 
institutional practices.
2.Be able to comply  with the protoco l for the duration of the study .
3.Be male or female from birth to <[ADDRESS_964763] 24hours after completion of study  drug administration .Subjects who are not 
receiving antibacterial treatment for the qualify ing infection at the time of screening 
are eligible for this trial if either (1) they will be initiating antibacterial treatment for 
the qualify ing infection prior to study  drug administration ,or (2) they have recently  
(within 48 hours prior to study  drug administration) completed antibacterial treatment 
for the qualify inginfection.
6.Meet 1 of the following categories:
a)The subject is a male who is not of reproductive potential, defined as a male who 
has azoospermia (whether due to having had a vasectom y or due to an underl ying 
medical condition).
b)The subject is a female who is not of reproductive potential, defined as a female 
who either: (1) who has not undergone menarche ,(2) has had a hysterectomy  and/or 
bilateral oophorectom y, bilateral salpi[INVESTIGATOR_8820] y, or bilateral tubal ligation/occlusion 
at least 6 weeks prior to screening ,OR (3) has a congenital or acquired condition that 
prevents childbearing.
c)The subject is a female or a male who is of reprod uctive potential and agrees to 
avoid becoming pregnant or impregnating a partner from the time of consent through 
[ADDRESS_964764] ying with 1 of the 
following:  (1) practice abstinence from heterosexual activity  OR (2) use (or have 
their partner use) acceptable contraception during heterosexual activity . Acceptable 
methods of contraception are:
Single method ( 1 of the following is acceptable):
Intrauterine device
Vasectom y of a female subject’s male partn er
Contraceptive rod implanted into the skin 
  059MV0
Product:   MK-7655A 25
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialCombination method (requires use of 2 of the following):
Diaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermicide)
Cervical cap with spermicide (nulliparous women only )
Contraceptive sponge (nulliparous women only )
Male condom or female condom (cannot be used together)
Hormonal contraceptive: oral contraceptive pi[INVESTIGATOR_4382] (estrogen/progestin pi[INVESTIGATOR_401115] -only pi[INVESTIGATOR_4382]), contraceptive skin patch, vaginal contraceptive ring, 
or subcutaneous contraceptive injection
Abstinence (relative to heterosexual activity ) can be used as the sole method of 
contraception if it is consistently  employ ed as the subject’s preferred and usual 
lifesty le and if considered acceptable by  [CONTACT_709644] a nd Ethical Review 
Committee (ERCs )/Institutional Review Boards (IRBs ). Periodic abstinence (eg, 
calendar, ovulation, sympto -thermal, post-ovulation methods, etc.) and withdrawal 
are not acceptable methods of contraception.
If a contraceptive method listed above is restricted by [CONTACT_427]/guidelines, 
then it does not qualify  as an acceptable method of contraception for subjects 
participating at sites in this country/region.
7.Have clinicall y stable renal function at the time of screening that is judged to be 
within acceptabl e ranges for age, as measured by [CONTACT_709645] 12.3.
8.Have sufficient intravascular access to receive study  drug through an existing  
peripheral or central line .
Subject Exclusion Criteria
The subject must be excluded from participating in the trial if the subject:
1.Has a personal history  of hy persensitivity  to IMIor to any  of the following:
Any carbapenem, cephalosporin, penicillin, or other β -lactam agent
Other BLIs (eg, tazobactam, sulbacta m, clavulanic acid, avibactam)
2.If female, is currentl y pregnant or breast feeding or has a positive serum β-human 
chorionic gonadotropin (β-hCG) pregnancy  test prior to administration of the study 
drug.
3.Has a history  of a seizure disorder (requiring ongoing treatment with anti-convulsive 
therap y or prior treatment with anti -convulsive therapy within the last 3 years).
4.Has used or plans to use valproic acid or divalproex sodium within [ADDRESS_964765]:   MK-7655A 26
Protocol/Amendment No.: 020-[ADDRESS_964766] PK sa mple collection .
6.Has used or plans to useany of the following medications, which areorganic anion 
transporter (OAT ) [ADDRESS_964767] PK sample collection : cimetidine, probenecid, 
indomethacin, mefenamic acid, furosemide or other loop diuretics (eg, bumetanide, 
torsemide, ethacry nic acid) , angiotensin receptor blockers (eg, valsartan) , and 
ketorolac.
7.Is currently  participating in or has participated in an interventional clinical trial with 
an investigational compound or device within [ADDRESS_964768]’s participation for 
the full duration of the trial.
11.Is expected to survive less than 72hours after completion ofstudy  drug 
administration.
12.Has any of the following laboratory  abnormalities at the time of screening (with the 
exception of values, as determined by [CONTACT_093], that would be part of normal 
physiologic process for a particular age group [eg, physiologic hyperbilirubinemia in 
a newborn ]):
ALT or AST ≥3 × ULN,
ALT or AST ≥2 × ULN accompanied b y total bilirubin >ULN,
Total bilirubin ≥2× UL N, or
Any other clinically  significant abnormal laboratory  test results not related to 
the underl ying infection, as determined by  [CONTACT_093].
13.Has a history  of clinically  significant renal, hepatic, or hemod ynam ic instability  
(defined as a requirement for pharmacological intervention to manage blood pressure 
in the 24-hour window prior to enrollment).
14.Has planned use of cardiopulmonary  by[CONTACT_6476], extracorporeal membrane oxygenation, 
hemodialy sis, or peritoneal dialy sis during the study .
15.For Cohorts 1 through 3 only: Has weight outside of the 5th to 95th percentile based 
on age .
16.Is, at the time of signing informed consent, a user of recreational or illicit drugs or has 
had a recent history  (within the last y ear) of drug or alcohol abuse or dependence. 
  059MV0
Product:   MK-7655A 27
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential17.Has a planned blood transfusion within 24 hours of study  drug administration or 
expected before the end of the PK sampling.
18.Has had significant blood loss ( ≥5% of total blood volume) within 4 weeks before the 
screeni ng visit. Total blood volume can be estimated as 80 mL/kg of body  weight .
19.Is or has an immediate family  member (e.g., spouse ,parent/ legal guardian, sibling or 
child) who is investigational site or sponsor staff directly involved with this trial.
Trial Treatment(s)
The t reatment to be used i n this trial isoutlined below in Table 1 .
Table 1 Trial Treatment
Drug Dose/PotencyDose 
FrequencyRoute of 
AdministrationRegimen Use
IMI/RELaVaries based on age 
cohort (Table 2)
Maximum dosage : 
Single IV infusion 
of 
500 mg IMI / 
250 mg RELSingle 
doseIVbVisit 2 
(Study 
Day 1)Experimental
Abbreviation: IMI/REL: imipenem/cilastatin/relebactam
aIMI/REL will be provided as a fixed -dose combination in a single vial.
bInfused over 30 (±5) minutes (initial infusion duration for Cohorts 1 through 3; see Section [IP_ADDRESS].1 for modifications for 
these age cohorts) or 60 (±5) minutes ( initial infusion duration for Cohorts 4 and 5) .
A single IV dose of IMI/REL will be administered to subjects any time after initiating 
standard- of-care treatment for a confirmed or suspected Gram -negative bacterial infection.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribution and usage of trial 
treatments in accordance with the protocol and an y applicable laws and regulations.
Dose Selection/Modification
Dose Selection (Preparation)
Table 2display s the proposed initial doses of the study  drug for each age cohort . The 
proposed initial doses may be modified as described in Section [IP_ADDRESS] –Dose Modification .
The dose modifications for Cohorts [ADDRESS_964769] interim 
review in these cohorts (ie, after 50% enrollment; see Section8.7) are described in 
Section [IP_ADDRESS].1 , along with the results of the second interim review (ie, following 
completion of enrollment in Cohorts 1 through 3) that led to the initial doses forCohorts [ADDRESS_964770]:   MK-7655A 28
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialTable 2 Imipenem/Ci lastatin/Relebactam (IMI/REL) Doses by [CONTACT_709646]/REL 
Proposed Initial Dosea
1(n=6) 12 to <18 years 15/7.5mg/kgover 30 min
2(n=6) 6 to <12 years 15/7.5mg/kg over 30 min
3(n=6) 2 to <6 years 15/7.5mg/kg over 30 min
4(n=8) 3 months to <2 yearsb10/5 mg/kg over 60 minc
5(n=18) Birth to <3 monthsd10/5 mg/kg over 60 minc
Abbreviations: IMI/REL: imipenem/cilastatin/relebactam; TBD: to be determined
aThe proposed initial doses may be modified based on interim data as described in Section [IP_ADDRESS] –Dose 
Modification .The dose modifications for Cohorts [ADDRESS_964771] interim 
review in these cohorts are described in Section [IP_ADDRESS].1. Single IV doses for all cohorts will not exceed the 
adult maximum dose of [ADDRESS_964772] 4 subjects in Cohort 4 w ill be <1 year of age .
cInitial doses of IMI/REL for subjects in Cohorts 4 and 5 wereselected based on PK modeling and simulation 
analyses, after incorporating observed PK data from Cohorts 1 through 3(Section [IP_ADDRESS].1) . Initial doses for 
Cohorts 4 and 5 w ere communicated to sites via a Protocol Clarification Letter.
dCohort 5 w ill be further subdivided into the following 3 age subcohorts:
4 weeks to <3 months of age; at least 6 subjects
1 to <4 w eeks of age; at least 6 subjects
<1 w eek of age; at least 6 subjects
The rationale for selection of doses to be used in this trial is provided in Section 4.0–
Background & Rationale. Additional details for preparation and administration of study  drug 
are provided in a separate Pharmacy  Manual.
Dose Modification
The goal of this trial is to determine doses of IMI/REL for each pediatric age cohort that 
achieve similar therapeutic exposu re parameters as seen in clinical trials in adults and have 
an acceptable safety  profile. As such, all observed PK data will be entered into a rolling 
population PK model -based simulation. For each age cohort, the Sponsor will assess dose 
suitability during the planned interim review sbased on the observed PK and safety  data from 
the first half of subjects enrolled into the cohort .The following parameters will be considered 
in determination of pediatric doses :
Simulated population PK parameters for each age cohort approach the following 
values, as expected in adults :
oSingle -dose REL  exposure of AUC 0-∞≥37.5 μM-hr(and ≤200 μM-hr ). Doses 
associated with this exposure have been established as being well tolerated in 
adults.
o≥30% TMIC (within proposed dosing interval) for single -dose imipenem (and 
AUC 0-∞≤250 μM-hr). Doses achieving these targets have been established as 
safe and efficacious in adults . 
  059MV0
Product:   MK-7655A 29
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialObserved safet y data demonstrates an acceptable safet y profile, as defined by [CONTACT_709647]-threatening toxicities considered by [CONTACT_259114] .Life-threatening toxicities are defined as follows:
oFor laboratory  AEs, a grade of 4 on the Division of Microbiology  and 
Infectious Diseases pediatric toxicity  scale [12].
oFor clinical AEs, events that are considered serious due to being 
life-threatening, as defined in Section 7.2.4 –Evaluating Adverse Events and 
as documented on the electronic case report form (eCRF) .
Modified doses will not exceed the adult maximum of 500mg IMI and 250mg REL for a 
single IV dose, and dose modifications , if required ,will be communicated to sites via 
Protocol Clarification Letters.
Dose Modifications and Decisions After Interim Reviews
At the time of this protocol amendment (-02), enrollment into Cohorts [ADDRESS_964773] 50% of subjects in each age cohort. The dose modifications that were 
made as a result of the interim rev iews are show ninFigure 2.These dose modifications were 
communicated to sites via Protocol Clarification Letters and are based on the following
considerations :
At time of enrolling Cohorts 1 through 3, no pediatric -specific population PK model 
for imipenem and REL  was available; therefore, PK endpoints from these cohorts 
were estimated based on an allometrically -scaled adult population PK model. The 
interim reviews in each cohort showed that the scaled adult model appropriatel y 
described the observed imipenem and REL concentrations from pediatric subjects in 
Cohorts 1 through 3.
Cohort 1: At the initial dosing guidance of 15/7.5 mg/kg IMI/REL as a 30-minute IV 
infusion, all subjects received the full adult dose of 500/250 mg IMI/REL based on 
their weight. Based on modeling, likely weights of subjects 
in the age cohort would 
almost alway s necessitate the full 500/250 mg dose of IMI /REL; therefore, the dosing 
regimen was simplified to a flat single dose of 500/250 mg IMI/REL administered as 
a 30-minute IV infusion for the remaining subjects of Cohort 1.
Cohort 2: Simulations showed that by [CONTACT_709648] 30minutes to 60 minutes at the propo sed initial dose of 15/7.5 mg/kg IMI/REL, 
>90% of subjects in this age cohort would meet the protocol -defined safety  targets, 
and ~75% of subjects in this age cohort would meet PK targets for both imipenem 
and REL. Therefore, the dosing regimen was change d to 15/7.5 mg/kg IMI/REL as a 
60-minute intravenous infusion for the remaining Cohort 2 subjects in order to ensure 
the majority  of patients met the safet y and PK targets.
Cohort 3: Simulations showed that by [CONTACT_709649]/REL at 15/7.5 mg/kg over 
60minutes (rather than over 30minutes), ~98% of subjects in this age cohort would 
meet the protocol -defined safet y targets for both imipenem and REL . Furthermore, a 
change in the infusion period from [ADDRESS_964774]:   MK-7655A 30
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidentialupdated regim en for the remaining subjects in Cohort 2. Therefore, the dosing 
regimen was changed to 15/7.5 mg/kg IMI/REL as a 60-minute intravenous infusion 
for the remaining Cohort 3 subjects.
After completion of enrollment of Cohorts 1 through 3 (2 to <18 years of age), the protocol -
defined interim review of aggregate safety  and PK data from these 3 cohorts was conducted .
The observed safet y data for all 19 subjects who received IMI/REL demonstrated an 
acceptable safet y profile. PK data from the 18 PK evaluable subje cts were used to develop a
pediatric -specific population PK model for imipenem and relebactam. In order to extrapolate 
thedeveloped pediatric population PK model for the older cohorts ( 2 to <18 years of age) to 
Cohorts 4 and 5 (<2years of age), an adjust ment function was included to account for a lack 
of full renal maturation for the subjects in this age range . Simulations were conducted to 
project the initial doses for Cohorts 4 and 5. The dosing regimen specified in Table 2for 
Cohorts 4 and 5 was selected based on drug exposures that were projected to provide optimal 
probability  of safet y and efficacy.
For Cohort 4, simulations from t he interim review showed that infusing IMI/REL  at 
15/7.5 mg/kg (rather than 10/5 mg/kg) over 60 minutes would result in projected efficacy  and 
safet y targets similar to the evaluated initial Cohort 4 dose of 10/5 mg/kg. Furthermore, 
choosing a 15/7.5 mg/kgdose for the remaining 4 subjects enabled data collection over an 
expanded dosing range, and therefore support spopulation PK model optimization and future 
clinical use. Additionally , the 15/7.5 mg/kg dosing regimen of IMI/REL is consistent with 
the curre nt PRIMAXIN®/TI ENAM® (imipenem/cilastatin) dosing recommendations for 
pediatric patients, for which there is a long history of safe and efficacious use .
Figure 2Dose Modifications for Cohorts 1, 2, [ADDRESS_964775]:   MK-7655A 31
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Timing of Dose Administration
A single dose of IMI/REL will be administered as an IV infusion . The infusion durations for 
each age cohort areas follows:
Cohorts 1 through 3: subjects enrolled prior to the 50% interim review for each of 
these cohorts received a 30(±5)-minute infusion. Following the interim review (see 
Section [IP_ADDRESS].1 ), subjects in these cohorts received a 60 (±5) -minute infusion.
Cohort 4: subjects enrolled prior to the 50% interim review received a 
60(±5)-minute infusion. Following the interim review (see Section [IP_ADDRESS].1), 
remaining subjects in this cohort also received a 60 (±5) -minute infusion.
Cohort 5: 60 (±5) minutes . Any modification to this infusion duration following the 
planned interim reviews will be communicated via a Protocol Clarification L etter.
The dose can be administered any time after initiating standard -of-care treatment for a 
confirmed or suspected Gram -negative bacterial infection , but no more than 48hours
following the screening visit for this study and no more than [ADDRESS_964776] notbe administered 
simultaneously  through the same infusion line/lumen with any other drugs (including IV 
nonstudy  drugs). If another IV drug is required either prior to or after study  drug and only 1 
line/lumen is available, an appropriate volume of saline flush must be used between IV 
infusions.
Trial Blinding 
This is an open -label trial; therefore, the Sponsor, investigator and subject will know the 
treatment administered.
Randomization or Treatment Allocation
During the course of the study , subjects will be allocated to age cohorts by [CONTACT_709650]. After the informed consent form issigned by [CONTACT_709651], designated site study  staff will obtain the subject’s 
treatment/randomization number from a computer -generated code via interactive voice or 
web response sy stem ( IVRS or I WRS ).
Stratification
Treatment allocation/randomization will be stratified according to the following factors:
1.Age:  subjects will be allocated to age cohorts as described in Section 2.1 – Trial 
Design.
Concomitant Medications /Vaccinations (Allowed & Prohibited)
Medications or vaccinations specifically  prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for any medication or vaccination 
specificall y prohibited during the trial, discontinuation from trial therapy  or vaccination may  
  059MV0
Product:   MK-7655A 32
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidentialbe required.  The investigator should discuss any questions regarding this with the Sponsor 
Clinical Director.  The final decision on any supportive therap y or vaccination rests with the 
investigator and/or the subject's primary  physician.  However, the decision to continue the 
subject on trial therapy or vaccination schedule requires the mutual agreement of the 
investigator, the Sponsor and the subject ’s legally  acceptable representative .
Listed below are specific restrictions for concomitant therap y during the course of the trial:
1.Valproic acid or divalproex sodium within 2weeks prior to screening or at any point 
between screening and 24hours after the 
completion ofstudy  drug infusion.
2.Any carbapenem antibiotic within 48hours prior to initiation of study  drug infusion 
or at any point betwee n administration of study  drug and the last PK sample 
collection.
3.Has used or plansto use any  of the following medications, which are OAT1 or OAT3 
inhibitors, within [ADDRESS_964777] PK sample collec tion:cimetidine, probenecid, indomethacin, mefenamic acid, 
furosemide or other loop diuretics (eg, bumetanide, torsemide, ethacry nic acid) , 
angiotensin receptor blockers (eg, valsartan) , and ketorolac.
Rescue Medications & Supportive Care
No rescue or sup portive medications are specified to be used in this trial.
Diet/Activity/Other Considerations
Subjects will refrain from consumption of alcohol from screening through 24hours after the 
completion of study  drug infusion.
Subjects will avoid strenuous physical activity  (eg, weight lifting, running, bicycling) from 
screening through [ADDRESS_964778] Withdrawal/Discontinuation Criteria
Discontinuation of Treatment
Discontinuation of treatment (for this single -dose study , this would be discontinuation of 
study  drug partway  through the infusion) does not represent withdrawal from the trial.
As certain data on clinical events beyond treatment discontinuation may be important to the 
study , they must be collected through the subject’s last scheduled follow -up, even if the 
subject has discontinued treatment.  Therefore, all subjects who discontinue trial treatment 
prior to completion of the treatment will still continue to participate in the trial as specified in 
Secti on 6.0– Trial Flow Chart and Section [IP_ADDRESS] –Discontinued Subjects Continuing to be 
Monitored in the Trial.
Subjects may discontinue treatment at any time for any reason or be dropped from treatment 
at the discretion of the investigator should any untow ard effect occur.  In addition, a subject 
may be discontinued from treatment by [CONTACT_26354], the trial plan is violated, or for administrative and/or other safety  reasons.   
  059MV0
Product:   MK-7655A 33
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialSpecific details regarding procedures to be performed at treatment discontinuation are 
provided in Section 7.1.4 –Other Procedures.
A subject must be discon tinued from treatment but continue to be monitored in the trial for 
any of the following reasons :
oThe subject or subject’s legally acceptable representative requests to discontinue 
treatment .
oThe subject has a medical condition or personal circumstance that, in the opi[INVESTIGATOR_19348]/or S ponsor, place sthe subject at unnecessary  risk from continued 
administration of study  drug .
For subjects who are discontinued from treatment but continue to be monitored in the trial, 
see Section 6.0 – Trial Flow Chart, and Section [IP_ADDRESS] –Discontinued Subjects Continuing 
to be Monitored in the Trial for those procedures to be completed at each specified visit.
Discontinuation from treatment is “permanent.” Once a subject is discontinued, he/she shall 
not be allowed to restart treatment.
Withdrawal from the Trial
Subjects may  withdraw from the trial at any  time for any  reason.  If a subject withdraws from 
the tri al, they  will no longer receive treatment or be followed at scheduled protocol visits.
A subject must be withdrawn from the trial if:
○The subject or subject’s legal ly acceptable representative withdraws consent from the 
trial.
○The subject is lost to follow -up.
Specific details regarding procedures to be performed at the time of withdrawal from the trial 
are outlined in Section 7.1.4 – Other Procedures.
Subject Replacement Strategy
If a subject discontinues from trial treatment ,withdraws from the trial, or is missing PK 
samples, a replacement subject may be enrolled if deemed appropriate by [CONTACT_709652] a sufficient number of evaluable PK samples are collected in each age 
cohort.
The replacement subject will be assigned a unique treatment/randomization number by [CONTACT_709653]. The subject being replaced will still be included in the safety  analysis if they 
received an y stud y treatment.
Beginning and End of the Trial
The overall trial begins when the first subject signs the informed consent /assent form.  The 
overall trial ends when the last subject completes the last study-related phone -call or visit,
withdraws from the trial or is lost to follow -up (i.e. the subject is unable to be contact[CONTACT_103200]). 
  059MV0
Product:   MK-7655A 34
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Clinical Criteria for Early Trial Termination
The clinical trial may be terminated early if the extent (incidence and/or severity ) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the trial population as 
a whole is unacceptable.  In addition, further recruitment in the trial or at (a) particular trial 
site(s) may be stopped due to insufficient compliance with the protocol, GCP and/or other 
applicable regulatory  requirements, procedure -related problems or the number of 
discontinuations for administrative reasons is too high. 
  059MV0
Product:   MK-7655A 35
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential6.0TRIAL FLOW CHART
Trial Period: Screening Treatment Post-treatmentEarly 
Discontinuation1
Visit Title:1
Screening2 3 4 Unscheduled
Scheduled Day: –2 to 121 215
(In Person or by [CONTACT_10880])Unscheduled
Scheduling Window:24 (±8) hours after 
completion of 
study drug infusion +2 days Discontinuation
Administrative Procedures
Informed Consent/Assent3X
Inclusion/Exclusion Criteria X
Subject Identification Card X
Medical History X
Prior and Concomitant Medication Review4X X X X X
IMI/REL (Study Drug) Administration X
Clinical Procedures/Assessments
Full Physical Examination X
Directed Physical Examination X5X X
Height X
Weight X
Vital Sign Measurements (heart rate, blood pressure, 
respi[INVESTIGATOR_697], temperature)X X6X X
Adverse Events Monitoring X X X X X
Local Tolerability Monitoring X X X7
Laboratory Procedures/Assessments
Serum Pregnancy Test (if applicable)8X
Hem atology Sampling9X X X
Blood Chemistry Sampling9X X X
Urinalysis Sampling10X X X
Plasma Pharmacokinetic Sampling11X12 
  059MV0
Product:   MK-7655A 36
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential1.To be perform ed for all subjects who discontinue from treatment (ie, discontinue study drug partway through the infusion )or withdraw from the trial at any 
point after the start of study drug infusion .
2.Screening procedures must be completed within [ADDRESS_964779] -fed subjects .
5.To be p erform edbefore the start of study drug infusion .
6.To be performed (1) within 2hours before the start of study drug infusion ,(2) 15to 30minutes after completion of study drug infusion , and (3) 4.5 to 
6hours after the start of study drug infusion .
7.Only for subjects who discontinue from treatment or w ithdraw from the trial at any point betw een the start of study drug infusion and the Day 2 visit.
8. Fem ale subjects of child -bearing potential only.
9.If blood tests (chemistry and hematology) have been conducted at the local laboratory within 48 hours of dosing, they may be used (ie, they do not need to 
be repeated at screening for the purpose of the study).
10.Urine will be collected from subjects who are either toilet trained and able to provide a specimen, catheterized, or fitted with a urine collection bag.
11.The method of collection for pharmacokinetic samples is at the discretion of the investigator (eg, peripherally inserted central catheter line, indwelling 
catheter access, individual peripheral phlebotomies, peri-operatively placed arterial line). A separate IV line for PK sample collection is highly 
recommended; if a separate IV line is not clinically feasible, refer to the operations/laboratory manual for further details of allow able alternativ e collection 
methods.
12.Blood samples for plasma pharm acokinetic assessments will be collected at the following time points: (1) within 30minutes before the start of study drug 
infusion, (2) within 10minutes after the end of study drug infusion, (3) 1.5 to 2.5 hours (for Cohorts 1 through 4) or 2 to 5 hours (for Cohort 5) after the start 
of study drug infusion, and (4) 4.5 to 6 hours (for Cohorts 1 through 4) or 6 to 12 hours (for Cohort 5) after the start of study drug infusion. 
  059MV0
Product:   MK-7655A 37
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential7.0TRIAL PROCEDURES
Trial Procedures
The Trial Flow Chart -Section 6.0summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary  to 
perform these procedures at unscheduled time points if deemed clinically necessary  by [CONTACT_1275].
Furthermore, additional evaluations/testing may  be deemed necessary  by [CONTACT_26357] . In some cases, such evaluation/testing 
may be potentially  sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent , and assent if applicable, be obtained from the 
subject.  In these cases, such evaluations/testing will be performed in accordance with those 
regulations.
Administrative Procedures
Informe d Consent /Assent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent , and assent if applicable, from each potential subject or each 
subject’s legally  acceptable representative prior to partic ipating in a clinical trial. If there are 
changes to the subject’s status during the trial (e.g.,health or age of majority  requirements ), 
the investigator or medically  qualified designee must ensure the ap propriate consent /assent is 
in place. 
General Inf ormed Consent /Assent
Consent /assent must be documented by [CONTACT_423]’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s 
legally  acceptable representative’s dated signature [INVESTIGATOR_2394] a consent /assent form along with the 
dated signature [CONTACT_63564]. 
A copy of the signed and dated consent /assent form should be given to the subject before 
participation in the trial.
The initial informed consent /assent form, any subsequent revised written informed 
consent /assent form and any written information provided to the subject must receive the 
IRB/ERC’s approval/favorable opi[INVESTIGATOR_19349].  The subject or his/her legally 
acceptable representative should be informed in a timely  manner if new information becomes 
available that may be relevant to the subject’s willingness to continue participation in the 
trial.  The communication of this information will be provided and documented via a revised 
consent /assent form or addendum to the original consent /assent form that captures the 
subject’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally  acceptable representative’s dated 
signature.
Specifics about a trial and the trial population will be added to the consent /assent form 
template at the protocol level. The assent, as applicable, will adhere to IRB/ERC 
requi rements, applicable laws and regulations and Sponsor requirements.    
  059MV0
Product:   MK-7655A 38
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialThe informed consent will adhere to IRB/ERC requirements, applicable laws and regulations 
and Sponsor requirements.
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_63522] a qualified 
physician to ensure that the subject qualifies for the trial.
Subject Identification Card
All subjects and/or subjects’ parents or legally  acceptable representativ e (as appropriate) will 
be given a Subject Identification Card identify ing them as par ticipants in a research trial. The 
card will contain trial site contact [CONTACT_3031] (including direct telephone numbers) to be 
utilized in the event of an emergency . The investigator or qualified designee will provide the 
subject with a Subject Identification Card immediately  after the subject provides written 
informed consent /assent .At the time of treatment allocation/randomization, site personnel 
will add the treatment/randomization number to the Subject Identification Card.
The subject identification card also contains contact [CONTACT_75345] a health care provider can obtain information about trial 
medication/vaccination in emergency  situations where the investigator is not available.
Medical History
Relevant medical history will be obtained by  [CONTACT_27404]. Details of 
the qualify ing infection will be recorded.
Prior and Concomitant Medications Revie w
Prior Medications
The investigator or qualified designee will review prior medication use, including any 
protocol -specified washout requirement, and record prior medication taken by [CONTACT_49880] 7daysbefore screening .For breast -fed subjects, medications taken by [CONTACT_709654].
Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by [CONTACT_460170]. For breast -fed subjects, medications taken by [CONTACT_709655].
Assignment of Screening Number
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization or treatment allocation.  Each 
subject will be assigned only one screening number.  Screening numbers must not be re -used 
for different subjects. 
  059MV0
Product:   MK-7655A 39
Protocol/Amendment No.: 020-[ADDRESS_964780] who is screened multiple times will retain the original screening number 
assigned at the initial screening visi t.
Specific details on the screening visit requirements (screening/rescreening) are provided in 
Section [IP_ADDRESS] –Screening .
Assignment of Treatment/ Randomization Number
All eligible subjects will be allocated, by [CONTACT_105]-random assignment, and will receive a 
treatment/ randomization number.  The treatment/randomization number identifies the subject 
for all procedures occurring after treatment allocation /randomization .   O nce a 
treatment/ randomization number is assigned to a subject, it can never be re-assigned to 
another subject.
A single subject cannot be assigned more than 1 treatment/ randomization number.
Trial Compliance
Interruptions from the protocol specified treatment require consultation between the 
investigator and the Sponsor and written documentation of the collaborative decision on 
subject management.
Administration ofthe single dose oftrial medication will be witnessed by [CONTACT_40581]/or trial staff , and the time and date will be recorded in the subject’s eCRF .
Clinical Procedures/Assessme nts
Full and Directed Physical Examinations
All physical examinations must be performed by [CONTACT_63534] (consistent with local requirements) .
A complete physical examination performed at the screening visit includes the following 
assessments: general appearance, head, eyes, ears/nose/throat, neck, lymph nodes, skin, 
lungs, heart, abdomen, musculoskeletal, and neurologic evaluations. Rectal and 
genitourinary /pelvic exams should be performed when clinically  indicated. If a physical 
examination was performed within [ADDRESS_964781]’s illness and complaints will be performed at subsequent visits as specified in 
Section 6.0 – Trial Flow Chart.
Any abnormal or clinically  significant findings from the physical examinations must be 
recorded on the appropriate eCRF.
Height and Weight
The subject’s height and weight should be measured at screening. 
  059MV0
Product:   MK-7655A 40
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Vital Sign Measurements
Vital sign measurements should include heart rate, blood pressure, respi[INVESTIGATOR_2842], and oral 
temperature. Subjects should be in a seated or semi recumbent position prior to having vital 
sign measurements obtained. For those subjects who cannot sit upfor any reason (eg, 
neonates, infants, intubated subjects), vital sign measurements will be taken in a supi[INVESTIGATOR_709632]. Oral temperatures should be taken, but if oral is not possible, 
tympanic, rectal, or axillary  methods are acceptable.
Any abnormal or clinically  significant findings from the vital sign measurements must be 
recorded on the appropriate eCRF.
Adverse Event Monitoring
Please refer to Section 7.2–Assessing and Recording Adverse Events for details regarding 
assessment and documentation of AEs. Laboratory AEs will be based on safet y laboratory  
test results, including hematology  and chemistry  tests from blood and urinalysis from urine. 
AllAEs should be documented on the appropriate eCRF. Refer to Section 7.1.3 –Laboratory 
Procedures/Assessments and Section 6.0– Trial Flow Chart for more details on ty pes of tests 
and timing of collection.
Local Tolerability Monitoring
Local infusion site tolerability  will be evaluated at the time points specified in Section 6.0–
Trial Flow Chart . The tolerability  of all study  therap y at the local IV infusion site will be 
based on investigator inspection and, when applicable, subject comments regarding sig ns and 
symptoms of intolerance. The IV infusion site should be observed to determine the 
presence/absence of erythema, induration, pain, tenderness, warmth, swelling, ulceration, 
local phlebitis, rash, or other reactions.
Laboratory Procedures/Assessments
Details regarding specific laboratory  procedures/assessments to be performed in this trial are 
provided below. The total amount of blood to be drawn over the course of the trial (from 
pre-trial to post-trial visits), including approximate blood volumes drawn by [CONTACT_709656] ,can be found in Appendix 12.2 –Approximate Blood/Tissue 
Volumes Drawn/Collected by  [CONTACT_709657].
Laboratory Safety Evaluations (Hematology, Chemistry ,and Urinalysis)
Laboratory  tests for hema tology , chemistry  and urinaly sis are specified in Table 3 .
Clinically  stable renal function, as measured by [CONTACT_36574] (see Appendix 12.3) , is 
an inclusion criterion for this trial. In addition to values obtained from scheduled chemistry  
blood draws during the study , the serum creatinine values used to calculate creatinine 
clearance for eligibility  determination will also be recorded on the ap propriate eCRF.
Urine will be collected from subjects who are either toilet trained and able to provide a 
specimen, catheterized, or fitted with a urine collection bag. 
  059MV0
Product:   MK-7655A 41
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialTable 3 Laboratory  Tests
Hematology Chemistry Urinalysis Other
Hematocrit Albumin Blood Serum β-hCGa
Hemoglobin Alkaline phosphatase Glucose
Platelet count ALT Protein
WBC count (total 
and differential)AST Specific gravity 
Neutrophils 
(%, absolute)Bicarbonate Microscopic exam, if 
abnormal results are noted
Band 
neutrophils 
(%, absolute)Calcium pH
Lymphocytes 
(%, absolute)Carbon dioxide
Eosinophils 
(%, absolute)Chloride
Basophils 
(%)Creatinine
Glucose
Phosphorus
Potassium
Sodium
Total bilirubin
Direct and indirect bilirubin, 
if total bilirubin is elevated 
above the ULN
Total protein
Blood urea nitrogen
Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; β-hCG: β-human chorionic 
gonadotropin; ULN: upper limit of normal; WBC: white blood cell.
a.Female subjects of child -bearing potential only.
Pharmacokinetic/Pharmacodynamic Evaluations
Four PK samples per subject will be collected in each of the age cohorts as follows:
1.First PK sample: predose sample taken within 30minutes before the start of study 
drug infusion.
2.Second PK sample: collected within [ADDRESS_964782] PK sample:
Cohorts 1through 4: obtained 1.5 to 2.5 hours after the start of study  drug 
infusion.
Cohort 5: obtained [ADDRESS_964783]:   MK-7655A 42
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential4.Fourth PK sample:
Cohorts 1through 4: obtained 4.5 to 6 hours after the start of study  drug 
infusion.
Cohort 5: obtained [ADDRESS_964784].
The following model -based and derived PK parameters will be calculated for REL and/or
imipenem, as appropriate:
AUC 0-∞
Cmax
%TMI C (imipenem only)
Systemic clearance (CL)
Centr al volume of distribution (Vc)
The following noncompartmental analy sis (NCA )-based PK parameters will be calculated for 
cilastatin:
AUC 0-∞
Time to maximum observed plasma drug concentration
Concentration at end of infusion (C EOI)
t1/2
CL
Volume of 
distribution (Vss)
Blood Collection for Plasma MK-7655A
Sample collection, storage ,and shipment instructions for plasma samples will be provided in 
theoperations/laboratory manual .
The method of collection for PK samples is at the discretion of the investigator (eg, 
peripherally  inserted central catheter line, indwelling catheter access, individual peripheral 
phlebotomies, peri-operatively  placed arterial line). A separate IV line for PK sample 
collection is highly  recommended; if a separate IV line is not clinically  feasible, refer to the 
operations/laboratory  manual for further details of allowable alternative collection methods. 
  059MV0
Product:   MK-7655A 43
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Other Procedures
Withdrawal/Discontinuation
Subjects who discontinue treatment prior to completion of the treatment regimen (ie, 
discontinuation of study drug partway  through the infusion )should be encouraged to 
continue to be followed for all remaining study visits.
When a subject discontinues/withdraws from participation in the trial, all applicable activities 
scheduled for the early withdrawal trial visit, as specified in Section 6.0– Trial Flow Chart,
should be performed at the time of discontinuation.  Any adverse events which are present at 
the time of discontinuation/withdrawal should be followed in accordance with the safety  
requirements outlined in Section 7.[ADDRESS_964785] Blinding/Unblinding
This is an open label trial; there is no blinding for this trial.
Domiciling
In order to participate in this study , subjects must be hospi[INVESTIGATOR_709633] 24 hours after completion of study  drug administration.
Calibration of Equipment
The investigator or qualified designee has the responsibility  to ensure that any device or 
instrument used for a clinical evaluation/test during a clinical study  that provides information 
about inclusi on/exclusion criteria and/or safet y or efficacy  parameters shall be suitably  
calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.
Visit Requirements
Visit requirements are outlined in Section 6.0-Trial Flow Chart. Specific procedure -related 
details are provided above in Section 7.1 - Trial Procedures.
Screening
Within 48hours prior to the start of study  drug infusi on, potential subjects will be evaluated 
to determine that they fulfill the entry  requiremen ts as set forth in Section 5.1–Entry 
Criteria .Screening procedures may be repeated after consultation with the Sponsor. If the 
subject is rescreened, screening procedures should be repeated, unless they fall within the 
window specified. 
  059MV0
Product:   MK-7655A 44
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Treatment Period
Details regarding procedures, assessments, andscheduling windows for the single treatment 
visit (ie, Visit 2) are presented in Section 6.0 –Trial Flow Chart. Notably , blood samples for 
plasma PK assessments and vital sign measurements will be collected several times at Visit 2 
(see Section 6.0–Trial Flow Chart for further details) .
Discontinued Subjects Continuing to be Monitored in the Trial
Subjects that discontinue treatment (ie, subjects that discontinue from study  drug partway 
through the infusion) or who withdraw from the trial at any  point after the start of study  drug 
infusion should have all safet y assessments, including clinical safet y laboratory  assessments, 
vital sign measurements, directed physical examination, collection of AEs and concomitant 
medications, and local tolerability  monitoring (for subjects who discontinue from treatment 
or withdraw from the trial between the start of study  drug infus ion and the Day 2 visit)
completed as per Section 6.0– Trial Flow Chart , but do not need to have PK sampling 
performed.
Subjects that withdraw from the trial prior to receiving a dose of study  drug(eg,due to 
removal of consent by [CONTACT_26361], or due to an emergent condition or circumstance 
which, in the opi[INVESTIGATOR_94367], places the subject at unnecessary  risk 
through continued participation, or does not allow adherence to the protocol) do not need to 
undergo further visits or assessments.
Post-Trial
Subjects will be required to either return to the study  siteor have a telephone contact 
[CONTACT_3450]  [ADDRESS_964786] a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding, for example), 
symptom, or disease temporally  associated with the use of a medicinal product or protocol -
specified procedure, whether or not consider ed related to the medicinal product or protocol -
specified procedure.  Any worsening (i.e., any clinically  significant adverse change in 
frequency  and/or intensity ) of a preexisting condition that is temporally  associated with the 
use of the Sponsor’s produ ct, is also an adverse event.
Changes resulting from normal growth and development that do not vary significantl y in 
frequency  or severit y from expected levels are not to be considered adverse events.  
Examples of this may include, but are not limited to, teething, typi[INVESTIGATOR_26336] a ph ysiologically  appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol -specified procedure, whether investigational (including placebo  
  059MV0
Product:   MK-7655A 45
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidentialor active comparator medication) or marketed, manufactured by, licensed by, provided by [CONTACT_75365].
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accidental or intentional), from abuse and from withdrawal.
All adverse events that occur after the consent form is signed but before treatment 
allocation/ randomization must be reported by [CONTACT_105943], or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure. From the time of treatment allocation/ randomization through [ADDRESS_964787] be reported by [CONTACT_093]. Such events 
will be recorded at each examination on the Adverse Event case report forms/worksheets.  
The reporting timeframe for adverse events meeting any serious criteria is described in 
section [IP_ADDRESS]. The investigator will make every attempt to follow all subjects with non-
serious adverse events for outcome.
Electronic reporting procedures can be found in the Electronic Data Capture (EDC )data 
entry  guidelines. Paper reporting procedures can be found in the Investigator Trial File 
Binder (or equivalent).
Definition of an Overdose for This Protocol and Reporting of Overdose to the 
Sponsor
In this trial, an overdose is any dose higher than 10% of the calculated age-appropriate dose
specified in Section [IP_ADDRESS] –Dose Selection (Preparation) or in subsequent Protocol 
Clarification Letters .
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product or 
vaccine, the adverse event(s) is reported as a non-serious adverse event, unless other serious
criteria are met.
If a dose of Sponsor's product or vaccine meeti ng the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory  results, the overdose is 
reported as a non-serious adverse event , using the terminology  “accidental or intentional 
overdose without adverse effe ct.”
All reports of overdose with and without an adverse event must be reported by [CONTACT_23514] 24 hours to the Sponsor either by [CONTACT_26365]. Electronic 
reporting procedures can be found in the EDC data entry  guidelines. Paper reporting 
procedures can be found in the I nvestigator Trial File Binder (or equivalent) .
Reporting of Pregnancy and Lactation to the Sponsor
Although pregnancy  and lactation are not considered adverse events, it is the responsibility  of 
investigators or their designees to report any pregnancy  or lactation in a subject 
(spontaneousl y reported to them) that occurs during the trial.
Pregnancies and lactations that occur after the consent form is signed but before treatment 
allocation/ randomization must be reporte d by [CONTACT_709658]  
  059MV0
Product:   MK-7655A 46
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidentialexcluded from the trial, or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure.  Pregna ncies and lactations that occur from the time of treatment 
allocation/ randomization through 14 days following cessation of Sponsor’s product must be 
reported by [CONTACT_32595].  All reported pregnancies must be followed to the 
completion/termination of the pregnancy . Pregnancy  outcomes of spontaneous abortion, 
missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, 
miscarriage and stillbirth must be reported as serious events (Important Medical Events). If 
the pregnancy  continues to term, the outcome (health of infant) must also be reported.
Such events must be reported within 24 hours to the Sponsor either by [CONTACT_90079]. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper 
reporting procedures can be found in the Investigator Trial File Binder (or equivalent).
Immediate Reporting of Adverse Events to the Sponsor
Serious Adverse Events
A serious adverse event is any adverse event occurring at any dose or during any use of 
Sponsor's product that:
●Results in death;
● Is life threatening;
●Results in persistent or significant disability /incapacity ;
●Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059];
●Is a congenital anomal y/birth defect;
●Is an other important medical event .
Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same timeframe 
as SAEs to meet certain local requirements. 
●Is a cancer;
●Is associated with an overdose .
Refer to Table 4for additional details regarding each of the above criteria.
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any serious adverse event, or follow up to a serious adverse event, 
including death due to any  cause, that occurs to any  subject must be reported within [ADDRESS_964788] to be excluded from the trial, or is the result of a 
protocol -specified interven tion, including but not limited to washout or discontinuation of 
usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 14 days 
following cessation of treatment, any  serious advers e event, or follow up to a serious adverse 
event, including death due to any  cause, whether or not related to the Sponsor's product, must 
be reported within 24 hours to the Sponsor either by [CONTACT_26365]. Electronic 
reporting procedures can befound in the EDC data entry  guidelines. Paper reporting 
procedures can be found in the I nvestigator Trial File Binder (or equivalent). 
  059MV0
Product:   MK-7655A 47
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialAdditionally , any serious adverse event, considered by [CONTACT_19427] a qualified 
physician to be related to the Sponsor's product that is brought to the attention of the 
investigator at any time outside of the time period specified in the previous paragraph also 
must be reported immediately  to the Sponsor.
All subjects with serious adverse events must be followed up for outcome.
Events of Clinical Interest
Selected non-serious and serious adverse events are also known as Events of Clinical I nterest 
(ECI) and must be reported to the Sponsor.
For the time period beginning when the consent form is signed until treatme nt 
allocation/ randomization, any  ECI, or follow up to an ECI , that occurs to any  subject must be 
reported within [ADDRESS_964789] to be excluded from the trial, 
or is the result of a protocol -specified intervention, includin g but not limited to washout or 
discontinuation of usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 14days 
following cessation of treatment, any ECI, or follow up to an ECI,whether or not related to 
the Sponsor’s product, must be reported within 24 hours to the Sponsor, either by [CONTACT_26366].  Electronic reporting procedures can be found in the EDC data entry 
guidelines.  Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent).
Events of clinical interest for this trial include:
1.an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit 
of normal and an elevated total bilirubin lab value that is greater than or equal to 2X 
the upper limit of normal and, at the same time, an alkaline phosphatase lab value that 
is less than 2X the upper limit of normal, as determined by [CONTACT_13149] -specified 
laboratory  testing or un scheduled laboratory  testing.*
*Note:  These criteria are based upon available regulatory  guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that may  require 
an additional evaluation for an underl ying etiology. The trial site guidance fo r assessment 
and follow up of these criteria can be found in the Investigator Trial File Binder (or 
equivalent).
2.a confirmed ( ie, verified by  [CONTACT_15013]) elevated AST or AL T laboratory  value that 
is greater than or equal to 5 ×ULN as a result of within -protocol -specific testing or 
unscheduled testing.
Evaluating Adverse Events
An investigator who is a qualified physician will evaluate all adverse events with respect to 
the elements outlined in Table 4. The investigator’s assessment of causality  is required for 
each adverse event.  Refer to Table [ADDRESS_964790]:   MK-7655A 48
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialTable 4 Evaluating Adverse Events
Maximum Mild awareness of sign or symptom, but easily tolerated  (for pediatric trials, awareness of symptom, but easily tolerated)
Intensity Moderate discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)
Severe incapacitating with inability to work or do usual activity (for pediatric trials, extremely distressed or unable to do usual activities)
Seriousness A serious adverse event (AE) is any adverse event occurring at any dose or during any use of Sponsor's product that:
†Results in death ; or
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred [Note: This does not include an 
adverse event  that, had it occurred in a more severe form, might have caused death.]; or
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059] (hospi[INVESTIGATOR_19357], regardless of length of stay, even if the 
hospi[INVESTIGATOR_2138] a precautionary measu re for continued observation.  (Note: Hospi[INVESTIGATOR_19358] a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre- existing condition is a clinical condition that is diagnosed prior to the use of a [COMPANY_006] product and is documented in the 
patient’s medical history. ); or
†Is a congenital anomaly/birth defect  ( in offspring of subject taking the product regardless of time to diagnosis); or
Is a cancer (although not serious per IC Hdefinition, is reportable to the Sponsor within 24 hours to meet certain local requirements );or
Overdose, although not serious per ICH definition, whether accidental or intentional, with or without an accompanying adverse event/serious adverse event, is
reportable to the Sponsor within [ADDRESS_964791] and may requi re medical or surgical intervention to prevent one of the outcomes listed 
previously (designated above by a †).
Duration Record the start and stop dates of the adverse event.  If less than 1 day, indicate the appropriate length of time and units
Action taken Did the adverse event cause the Sponsor's product to be discontinued?
Relationship to 
Sponsor's 
ProductDid the Sponsor's product cause the adverse event? The determination of the likelihood that the Sponsor's product caused the adverse event will be provided by [CONTACT_26368] a qualified physician.  The investigator’s signed/dated initials on the source document or worksheet thatsupports the causa lity noted on the AE 
form, ensures that a medically qualified assessment of causality was done.  This initialed document must be retained for the required regulatory time frame.  The 
criteria below are intended as reference guidelines to assist the investi gator in assessing the likelihood of a relationship between the test drug and the adverse event 
based upon the available information
The following components are to be used to assess the relationship between the Sponsor's product and the AE; the greater th e correlation with the components 
and their respective elements (in number and/or intensity), the more likely the Sponsor's product caused the adverse event:
Exposure Is there evidence that the subject was actually exposed to the Sponsor's product such a s:  reliable history, acceptable compliance assessment (pi[INVESTIGATOR_9650], diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the Sponsor's product? 
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal product)?
Likely Cause Is the AE notreasonably explained by [CONTACT_26369], other drug(s)/vaccine(s), or other host or environmental
factors 
  059MV0
Product:   MK-7655A 49
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialRelationship The following components are to be used to assess the relationship between the Sponsor's product and the AE:  (continued)
to Sponsor's 
Product
(continued) Dechallenge Was the Sponsor's product discontinued or dose/exposure/frequency reduced?
      If yes, did the AE resolve or improve?
           If yes, this is a positive dechallenge.    If no, this is a negative dechallenge.
(Note:  This criterion is not applicable if:  (1) the AE resulted in death or permanent disability; (2) the AE resolved/impro ved despi[INVESTIGATOR_538294] r's product; (3) the trial is a single -dose drug trial); or (4) Sponsor's product(s) is/are only used one time.)
Rechallenge Was the subject re- exposed to the Sponsor's product in this trial?
      If yes, did the AE recur or worsen?
          If yes, this is a positive rechallenge.    If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose drug trial); 
or (3) Sp onsor's product(s) is/are used only one time.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY [CONTACT_26370]'S PRODUCT, OR IF RE -EXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL 
SIGNIFIC ANT RISK TO THE SUBJECT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY [CONTACT_26371]/INDEPENDENT ETHICS COMMITTEE.
Consistency 
with Trial 
Treatment 
ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or drug class  
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by [CONTACT_19427] a qualified ph ysician according to his/her best clinical judgment, including 
consideration of the above elements.
Record one of the following : Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product rel ationship ).
Yes, there is a reasonable 
possibility of Sponsor's product 
relationship.There is evidence of exposure to the Sponsor's product.  The temporal sequence of the AE onset relative to the administration of the Sponsor's 
product is reasonable.  The AE is more likely explained by [CONTACT_1034]'s product than by [CONTACT_5748]. 
No, the re is not a reasonable 
possibility of Sponsor's product 
relationshipSubject did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor' s product is not 
reasonable OR the AE is more likely explained by [CONTACT_26372]’s product .  (Also entered for a subject with overdose without 
an associated AE.) 
  059MV0
Product:   MK-7655A 50
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Sponsor Responsibility for Reporting Adverse Events
AllAdverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations , i.e., per ICH Topic E6 (R1) 
Guidelines for Good C linical Practice .
8.0STATISTICAL ANALYSIS PLAN
This section outlines the statistical analy sis strategy  and procedures for the study . If, after the 
study  has begun, but prior to any  final database lock ,changes are made to primary  and/or key 
secondary  objecti ves, or the related statistical methods, then the protocol will be amended 
(consistent with ICH Guideline E9). Changes to exploratory  or other nonconfirmatory 
analyses made after the protocol has been finalized, but prior to final database lock, will be 
documented in a supplemental Statistical Analy sis Plan and referenced in the Clinical Study  
Report (CSR) for the study . Post hoc exploratory analyses will be clearly identified in the 
CSR. No separate Statistical Anal ysis Plan will be issued for this study .
Statistical Analysis Plan Summary
Key elements of the Statistical Analysis Plan are summarized below; the comprehensive plan 
is provided in Section 8.2 –Responsibility  for Analy ses/In -House Blinding through 
Section 8.9 – Sample Size and Power Calculations .
Study Design Overview A Phase 1b, Open -label, Single -dose Study to Evaluate the 
Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric 
Subjects From Birth to Less Than 18 Years of Age With Confirmed or 
Suspected Gram -negative Infections
Treatm entAssignment Single IV do seof MK -7655A (IMI/REL)
Analysis Popu lations Pharm acokinetic s: Per Protocol : all subjects who comply with the 
protocol sufficiently to ensure that their data will be likely to exhibit 
the prim ary endpoints, according to the underlying scientific model, 
and who have at least 1 postdose PK data point .
Safety: All Subjects as Treated (ASaT) : All subjects who received 
infusion (including partial doses) of study medication .
Prim ary Endpoint(s) Pharm acokinetic :Plasma PK concentration data; 4PK samples per 
subject will be collected .Primary model-based endpoints for REL and 
imipenem and non-model -based endpoints for cilastatin are listed in 
Section 8.4.1 –Pharmacokinetic/Pharmacodynamic Endpoints .
Secondary Endpoints Safety : Safety evaluation will be based on the follow ing endpoints : 
AEs (including ECIs), local tolerability assessments, clinical 
laboratory data, vital sign measurements, and physical exam ination s
findings . 
  059MV0
Product:   MK-7655A 51
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialModeling and Simulation
(M&S) Methods for Key 
Pharm acokinetic AnalysesPediatric REL and imipenem data will be used todetermine pediatric 
PK parameters by [CONTACT_709659] a starting 
point . The PK parameters will becontinuously updated as pediatric 
PK data become available from each age cohort. A nonlinear mixed 
effect smodelingapproach w ill be applied for model building.
The target isAUC 0-∞≥37.5 μM-hr(and ≤200 μM-hr) for REL and
TMIC ≥30% (and AUC 0
-∞≤250 μM-hr) for imipenem .The goal of 
model-based simulations will beto derive a dosing regimen where 
these predefined target s are jointly achieved in a proportion of
pediatric subjects similar ly covered in adult s(~90% probability of 
target attainment) for each age cohort .
For cilastatin ,
descriptive statistics will be provided for PK paramete rs 
by [CONTACT_50802], based on NCA.
Details on modeling andsimulation (M&S )methods are provided in 
Section 8.6.1 –Modeling & Simulation Methods for Pharmacokinetic 
Analyses .
Statistical Methods for 
Safety AnalysesDescriptive statistics will be provided for all safety assessments
described above .
Interim Reviews Interim reviews of PKand safety data are planned at 3stages in the 
study . Dose modification may be suggested based on interim revie w 
results. The planned interim reviews are summarized in Section 8.7–
Interim Review for Potential Dose Adjustment .
Multiplicity No m ultiplicity adjustment is planned .
Sample Size and Power Based on PK Precisio n
Proposed nu mber of study participants by p ediatric subset :
Cohort 1 (age 12 to < 18 years) ;at least 6 subjects
Cohort 2 (6 to < 12 years) ;at least 6 subjects
Cohort 3 (2 to < 6 years) ;at least 6 subjects
Cohort 4(3 months to <2 years) ;at least 8subjects , at least 4 of 
whom are <1 year of age
Cohort 5(birth to <3 months) ;at least [ADDRESS_964792] 
6younger neonates (<1 week age), at least 6 olderneonates (1 to 
<4weeks age), and at least 6 infan ts (4 w eeks to < 3 months )
Details on sample size calculation are provided in Section 8.9–
Sample Size and Pow er Calculations .
Responsibility for Analyses/In -House Blinding
The statistical analysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor .The analyses and summaries described in 
Section 8.6.1 –Modeling & Simulation Methods for Pharmacokinetic Analy sesare the 
responsibility  of the Quantitative Pharmacology and Pharmacometrics group andtheEarly 
Clinical Development Statistics group of the Sponsor .
This trial is being conducted as anonrandomized, open -label study  (ie, subjects, 
investigators, and Sponsor personnel will be aware of subject treatment assignments after 
each subject is enrolled and treatment is assigned ). 
  059MV0
Product:   MK-7655A 52
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialSubjects participating in this trail will be allocated to age cohorts as described in 
Section 2.1– Trial Design . The Clinical Biostatistic s department will generate the allocation 
schedule, and a llocation/non -random assignment will be implemented in an IVRS or IWRS .
There are no plans to conduct formal interim analy ses in this study . Planned interim reviews
of PK and safety  data for each agecohort are described in Section 8.7–Interim Review for 
Potential Dose Adjustment. An i nternal M&S team will be appointed toreview the PK 
profile and safet y and tolerability  data for each age cohort when PK data from 50% of 
subjects in each cohort is available .Dose modification may  be suggested based on the results 
of interim reviews as described in Section [IP_ADDRESS] –Dose Modification.
Hypotheses/Estimation
Objectives of the study are stated in Section 3.0–Objective (s)and Hypothesis(es) . No 
hypothe sis testing will be performed for this study .
Analysis Endpoints
Pharmacokinetic /Pharmacodynamic Endpoints
Plasma concentrations of REL, imipenem, and cilastatin will be determined. The REL and 
imipenem data will be used to develop a pediatric population PK model , which will be used 
to perform simulations to derive suitable pediatric doses. Cilastatin data will be used to 
summarize its PK profile based on NCA .
For REL, plasma exposure (AUC 0-∞) and Cmaxwill be the primary endpoint s. For imipenem, 
%TMI C,plasma exposure (AUC 0
-∞),and C maxwill be the primary  endpoints. In addition, the 
following model -based population mean PK parameters for both REL and imipenem will be 
determined: CL andVc.
For cilastatin , the following PK parameters will be determined: AUC 0-∞, CEOI, t1/2, CL,and 
Vss.
Safety Endpoints
A description of safet y meas ures is contained in Section 7.0– Trial Procedures .Safet y 
assessments will include AEs, local tolerability  assessments, clinical laboratory  evaluations, 
vital sign measurements, and phy sical examinations.
Analysis Populations
Pharmacokinetics Population
The Per Protocol population will be used for the PK analy sis. This population is the set of 
data generated by [CONTACT_709660] y to ensure 
that these data will be likely  to exhibit the primary  endpoints, according to the underly ing 
scientific model . Compliance covers such considerations as exposure to treatment, 
availability  of measurements ,and absenc e of major protocol violations. Subjects with major 
protocol violations will be identified to the extent possible by  [CONTACT_709661]  
  059MV0
Product:   MK-7655A 53
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidentialcollection/com pliance and its analy sis and interpretation. Any subjects or data values 
excluded from analysis will be identified, along with their reasons for exclusion, in the CSR. 
At the end of the trial, all subjects who are compliant with the trial procedure as described 
and have at least 1 postdose PK data point available will be included in the primary  PK 
analysis dataset.
Safety Analysis Populations
The All Subjects as Treated (ASaT) population will be used for the analy sisof safet y data in 
this study . The ASaT population consists of all allocated subjects who received infusion
(including partial doses) ofstudy  medicatio n.
Statistical Methods
Modeling & Simulation Methods for Pharmacokinetic Analyses
Relebactam and imipenem data will be used to develop a pediatric population PK model by 
[CONTACT_709662], which will be
continuously  updated as pediatric PK data become available from each age cohort. Any 
missing postdose plasma concentrations will be treated as missing. Values below the limit of 
quantification will be assigned a value of zero. A nonlinear mixed effects modeling approach 
will be used for model building. A Modeling and Simulation Analy sis Plan with further 
details on the methodology  will be prepared and finalized before database lock and analysis 
of the data.
There will be no formal hypothesis testing. The target is AUC 0-∞≥37.5 µM-hr (and 
≤200µM-
hr) for REL and TMIC ≥30% (and AUC 0-∞≤250µM-hr ) for imipenem. The goal 
of model -based simulations will be to derive a dosing regimen where these targets are jointl y 
achieved in a proportion of pediatric subjects similarly  covered in adults (~90% probability  
of target attainment) for each age cohort; hence, achieving these targets implies similar 
efficacy  as that obtained in adults. An absolute (mg) or weight -based (mg/kg) dose, 
whichever is found most suitable for each age cohort, will be selected based on the 
simulation results.
For cilastatin, an NCA will be conducted to determine its PK parameters. Descriptive 
statistics will be provided for cilastatin PK parameters b y age cohort.
Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed by  [CONTACT_709663], severit y, and type of AEs, changes in clinical laboratory  tests, and changes 
from baseline in vi tal sign measurements at the interim reviews and the end of study .
The type and incidence of all AEs and serious adverse events (SAEs) will be tabulated for 
each age cohort and dose level . The broad clinical and laboratory  AE categories consisting of 
the percentage of subjects with any AE, a drug-related AE, an SAE, a drug-related SAE, and 
who discontinued due to an AE, as well as the most frequentl y occurring individual AEs will 
be summarized in the same manner. Special attention will be given to local tolerability  events 
occurring at time of study  drug administration and to those subjects who discontinue due to  
  059MV0
Product:   MK-7655A 54
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidentialan AEor an SAE . Descriptive and/or summary  statistics for the raw laboratory safet y tests, 
vital sign measurements , and/or change s from baseline may also be computed, as deemed 
clinically  appropriate.
Interim Review sfor Potential Dose Adjustment
Interim reviews of PK and safet y data will occur at 3stages in the study . First, interim 
reviews were performed for each of Cohorts 1 through 3 in this study when data from 50% 
(3subjects) of subjects were available from a specific cohort. Second , an interim review of 
complete aggregated PK data from Cohorts [ADDRESS_964793], interim review sfor each of Cohorts 4 and5 will be performed when
data from 50% of subjec ts areavailable from a speci ficcohort . Results will be reviewed by 
[CONTACT_709664]. During the first and third interim reviews ,the suitability of the initial dose
for each age cohort will be assessed and a dose modification may be suggested for the
remaining 50% of subjects in tha tcohort, as described in Section [IP_ADDRESS] –Dose 
Modification. The dose modifications that occurred as a result of the completed interim 
reviews are described in Section [IP_ADDRESS].1.
Multiplicity
Because there are no pre -specified h ypotheses, no adjustments for multiplicity will be made.
Sample Size and Power Calculations
The p roposed number of study  participants by  [CONTACT_709665]:
Cohort 1 ( age 12 to <18 y ears) ; at least 6 subjec ts
Cohort 2 (6 to <12 y ears) ;at least 6 subjects
Cohort 3 (2 to <6 y ears) ;at least 6 subjects
Cohort 4 (3 months to <2 years);at least [ADDRESS_964794] 4 of whom are <1 year of 
age
Cohort 5 (birth to <3 months) ;at lea st [ADDRESS_964795] 6 younger neon ates 
(<1 week age), at least 6 older neonates (1 to <4 weeks age), and at least 6 infants 
(4weeks to <3 months)
A simulation -based methodology  was implemented in order to determine the appropriate 
sample size for each pediatric age cohort thatwould have at least 80% probability to achieve 
reasonable precisi on, defined as the 95% confidence interval within 60% to 140% of the 
population mean (approximately  ≤20% RSE [relative standard error] ), in the model -based 
estimation of primary  PK parameters for both REL and imipenem in each pediatric age 
cohort. Variability  in primary  PK parameters was assumed to be the same as that estimated in 
adults based on the adult population PK model (coefficient of variation (%CV )for 
imipenem: 50% for CL ,75% for Vc; %CV for REL : 40% for CL, 50% for Vc).
The proposed trial design, in terms of sample sizes combined with the PK sampling scheme, 
was found to be sufficient to have >80% probability (based on replicate simulations) to  
  059MV0
Product:   MK-7655A 55
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidentialachieve the defined target precision in mode l-based primary  PK parameter estimates (CL, 
Vc) for both REL and imipenem, and thus, isexpected to adequately  capture the PK 
characterization for both drugs in the pediatric population.
9.0LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL
SUPPLIES
Investigational Product
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribution and usage of 
investigational product in accordance with the protocol and any applicable laws and 
regulations.
Clinical Supplies will be provided b y the Sponsor as summarized in Table 5.
Clinical supplie s will be packaged to support enrollment and replacement subjects as 
required.  When a replacement subject is required, the Sponsor or designee needs to be 
contact[CONTACT_26380].
Table [ADDRESS_964796] Name & 
PotencyDosage Form Source/Additional Information
MK-7655A, 
MK-7655 250 mg/
Imipenem 500 mg/
Cilastatin 500 mgPowder for Constitution Provided centrall y by [CONTACT_709666] a clinical label in accordance with regulator y 
requirements.
Subjects will receive open- label, single -dose vials .No kitting is required .
Clinical Supplies Disclosure
This trial is open -label; therefore, the subject, the trial site personnel, the Sponsor and/or 
designee are not blinded. Treatment MK-7655A, MK -7655 250 mg, IMIPENEM 500 mg and 
CILASTAT IN EQUIVALENT 500 mg(name, strength or potency ) is included in the label 
text; random code/ disclosure envelopes or lists are not provided.
Storage and Handling Requirements
Clinical supplies must be stored in a secure, limited -access location under the storage 
conditions specified on the label.   
  059MV0
Product:   MK-7655A 56
Protocol/Amendment No.: 020-[ADDRESS_964797]/Destruction/ Returns and Reconciliation
The investigator is responsible for keepi[INVESTIGATOR_709634], the amount dispensed to and returned by [CONTACT_26383]. For all trial sites, the local country  Sponsor 
personnel or designee will provide appropriate documentation that must be completed for 
drug accountability  and return, or local discard and destruction if appropriate.  Where local 
discard and destruction is appropriate, the investigator is responsible for ensuring that a local
discard/destruction procedure is documented .
Standard Policies
Trial site personnel will have access to a central electronic treatment 
allocation/ randomization system (IVRS/I WRS system) to allocate subjects, to assign 
treatment to subjects and to manage the distribution of clinical supplies. Each person 
accessing the IVRS system must be assigned an individual unique PIN.  They must use only 
their assigned PIN to access the system, and they must not share their assigned PIN with 
anyone.
10.[ADDRESS_964798], ethics review committee (IRB/ERC) or similar 
or expert committee; affiliated institution and employ ees, only under an appropriate 
understanding of confidentiality  with such board or committee , affiliated institution and 
employ ees.  Data generated by [CONTACT_26384], 
except to the extent that it is included in a publication as provided in the Publications section 
of this protocol.
Confidentiality of Subject Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory  authority  representatives may consult and/or copy  trial documents in 
order to verify  worksheet/case report form data.  By [CONTACT_17317], the subject 
agrees to this process.  If trial documents will be photocopi[INVESTIGATOR_75311]/case report form information, the subject will be identified by [CONTACT_19494]; 
full names/initials will be masked prior to transmission to the Sponsor. 
  059MV0
Product:   MK-7655A 57
Protocol/Amendment No.: 020-[ADDRESS_964799] to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial manag ement purposes, as part of a regulatory  
submissions, and as required b y law.  This information may include:
1.name, address, telephone number and e -mail address;
2.hospi[INVESTIGATOR_26342];
3.curriculum vitae or other summary  of qualifications and credentials; and
4.other professional documentation.
Consistent with the purposes described above, this information may be transmitted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country  and other 
coun tries, including countries that do not have laws protecting such information.  
Additionally , the investigator’s name [CONTACT_26407] [CONTACT_709667].  By [CONTACT_12570], the investigator expressly  consents to these uses and 
disclosures.
If this is a multicenter trial, in order to facilitate contact [CONTACT_26387], the Sponsor 
may share an investigator’s name [CONTACT_3669] [CONTACT_35666] n with other participating 
investigators upon request.
Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
Compliance with F inancial Disclosure Requirements
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.  
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a  
  059MV0
Product:   MK-7655A 58
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
ConfidentialCertification/Disclosure Form, commonly  known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance with Law, Audit and Debarment
By [CONTACT_12570], the investigator agrees to conduct the trial in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of Good 
Clinical Practice (e.g., International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clini cal Practice: 
Consolidated Guideline and other generally  accepted standards of good clinical practice); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by  [CONTACT_44873], is provided in Section 12.[ADDRESS_964800] for Clinical Trials .
The investigator also agrees to allow monitoring, audits, IRB/ERC review and regulatory  
authority  inspection of trial- related documents and procedures and provide for direct access 
to all trial -related source data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance provid ers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator b y the Sponsor.
The investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submit any other reports to the 
Sponsor as required by [CONTACT_75389].
Trial documentation will be promptly  and fully disclosed to the Sponsor by [CONTACT_709668], 
copy ing, review and audit at reasonable times by [CONTACT_75391].  The investigator agrees to promptly  take any  reasonable steps that are 
requested b y the Sponsor as a result of an audit to cure def iciencies in the trial documentation 
and worksheets/case report forms.
The investigator must maintain copi[INVESTIGATOR_90047].  This 
documentation includes, but is not limited to, the protocol, worksheets/c ase report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory  authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory  reference ranges, laboratory  certification or 
quality  control procedures and laboratory  director curriculum vitae.  By  [CONTACT_12570], 
the investigator agrees that documentation shall be retained until at least [ADDRESS_964801]:   MK-7655A 59
Protocol/Amendment No.: 020-[ADDRESS_964802] consult 
with and obtain written approval b y the Sponsor prior to destro ying trial and/or subject files.  
ICH Good Clinical Practice guidelines recommend that the investigator inform the subject’s 
primary  physician about the subject’s participation in the trial if the subject has a primary  
physician and if the subject agrees to th e primary  physician being informed.
The investigator will promptly  inform the Sponsor of any regulatory  authority  inspection 
conducted for this trial.
Persons debarred from conducting or working on clinical trials by [CONTACT_90090]’s trials.  The investigator 
will immediately  disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
In the event the Sponsor prematurel y terminates a particular trial site, the Sponsor will 
promptly  notify  that trial site’s I RB/IEC.
According to European legislation, a Sponsor must designate an overall coord inating 
investigator for a multi -center trial (including multinational).  When more than one trial site 
is open in an EU country, [COMPANY_006], as the Sponsor, will designate, per country , a national 
principal coordinator (Protocol CI), responsible for coordinati ng the work of the principal 
investigators at the different trial sites in that Member State, according to national 
regulations.  For a single -center trial, the Protocol CI is the principal investigator.  In 
addition, the Sponsor must designate a principal or coordinating investigator [INVESTIGATOR_26344], to the best of his/her 
knowledge, the report accuratel y describes the conduct and results of the trial [Clinical Study  
Report (CSR) CI].  The Spons or may consider one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availabilit y of the Protocol/CSR 
CI during the anticipated review process, thorough understanding of clinical trial methods, 
appropriate enrollment of subject cohort, timely achievement of trial milestones).  The 
Protocol CI  must be a participating trial investigator.
Compliance with Trial Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Ame ndments Act (FDAAA) of 2007 
and the European Medicines Agency  (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the trial is solely  responsible for determining whether the trial and its results are subject to 
the requirements for submission to http://www.clinicaltrials.gov,  
  059MV0
Product:   MK-7655A 60
Protocol/Amendment No.: 020-[ADDRESS_964803] operating procedures (SOPs) to ensure that trials are conducted and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of Good Clinical Practice, and all appl icable federal, state, and local laws, rules and 
regulations relating to the conduct of the clinical trial.
Data Management
The investigator or qualified designee is responsible for recording and verify ing the accuracy 
of subject data.  By [CONTACT_12570], the investigator acknowledges that his/her 
electronic signature [CONTACT_75412] y binding equivalent of a written signature.  By [CONTACT_75393] g 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
Publications
This trial is intended for publication, even if terminated prematurel y. Publication may include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within [ADDRESS_964804]'s last visit for the 
primary  outcome, [ADDRESS_964805] 
marketing (dispensed, administered, delivered or promot ed), whichever is later. 
  059MV0
Product:   MK-7655A 61
Protocol/Amendment No.: 020-[ADDRESS_964806] to the confidentiality  agreement. 
When a manuscript is submitted to a biomedical 
journal, the Sponsor's policy  is to also 
include the protocol and statistical analy sis plan to facilitate the peer and editorial review of 
the manuscript.  If the manuscript is subsequently accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its website the key sections of the protocol that 
are relevant to evaluating the trial, specifically  those sections describing the trial objectives 
and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, 
the efficacy  and safet y measures, the statistical analy sis plan, and any  amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary  information.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrial s.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independentl y.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  In rare cases, publication of single trial site data prior to the main 
paper may be of value.  Limitations of single trial site observations in a multicenter trial 
should alway s be described in such a manuscript.
Authorship credit should be bas ed on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising 
it critically  for important intellectual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, [ADDRESS_964807] also been made to all three of the preceding authorship criteria.  Although 
publication planning may  begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made 
based on participation and actual contributions to 
the trial and writing, as discussed above. The first author is responsible for defending the 
integrit y of the data, method(s) of data anal ysis and the scientific content of the manuscript.
The Sponsor must have the opportunity  to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45days prior to submission for publication/presentation. 
Any information identified by [CONTACT_26395]; this confidentiality  does not include efficacy  and safety  results. Sponsor review 
can be expedited to meet public ation timelines.
11.[ADDRESS_964808] OF REFERENCES
1.Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, 
et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram -negative 
bacilli in critically  ill patients. Critical Care 20 03;7(5):R78 -R83.
2.Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, Vidal G, et al. Safety  and 
efficacy  of colistin in Acinetobacter and Pseudomonas infections:  a prospective cohort 
study . Intensive Care Med 2005;31:[ADDRESS_964809]:   MK-7655A 62
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential3.Pi[INVESTIGATOR_345774] V, García San Miguel L, Grill F, Mejía B, Cobo J, Fortún J, et al. Intravenous 
colistin sulphomethate sodium for therap y of infections due to multidrug -resistant gram -
negative bacteria. Journal of I nfection 2008;56:185 -90.
4.Chopra I, Schofield C, Everett M, O'Neill A, Miller K, Wilcox M, et al. Treatment of 
health- care-associated infections caused by [CONTACT_6907]-negative bacteria: a consensus 
statement. Lancet Infect Dis 2008;8:133 -9.
5.Boucher HW, Talbot GH, Bradley  JS, Edwards JE Jr, Gilbert D, Rice LB, et al. Bad 
bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society  of 
America. Clin Infect Dis 2009;48(1):1-12.
6.Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DS, Urassa WK, et al. High 
rate of fatal cases of pediatric septicemia caused by [CONTACT_152926]- negative bacteria with 
extended- spectrum beta-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol. 2005 
Feb;43(2):745 -
9.
7.Zaoutis TE, Goyal M, Chu JH, Coffin SE, Bell LM, Nachamkin I, et al. Risk factors for 
and outcomes of bloodstream infection caused by [CONTACT_89927] -spectrum beta-lactamase -
producing Escherichia coli and Klebsiella species in children. Pediatrics. 2005 
Apr;115(4):942-9.
8.Stone PW, Gupta A, Loughrey  M, Della -Latta P, Cimiotti J, Larson E, et al. Attributable 
costs and length of stay of an extended- spectru m beta-lactamase -producing Klebsiella 
pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epi[INVESTIGATOR_5541]. 
2003 Aug;24(8):[ADDRESS_964810] Dis. 2014 May;58(10):1439 -48.
10.Paterson DL, Bonomo RA. Extended- spectrum beta-lactamases: a clinical update. Clin 
Microbiol Rev. [ADDRESS_964811];18(4):657 -86.
11.Food and Drug Administration (CDER). General clinical pharmacology  considerations 
for pediatric studies for drugs and biological products [I nternet]. Silver Spring, MD: U.S. 
Department of Health and Human Services; 2014. Available from: 
http://www.fda.gov/ downloads/drugs/guidancecomplianceregulatory information/guidanc
es/ucm425885.pdf .
12.National Institute of Allergy  and Infectious Diseases. Division of microbiology  and 
infectious diseases (DMID) pediatric toxicity  tables [internet]. Bethesda, MD: NIAID; 
2007. Available from: 
https://www.niaid.nih.gov/sites/default/files/documents/dmidpedtox.pdf .
13.Brion LP, Fleischman AR, McCarton C, Schwartz GJ. A simple estimate of glomerular 
filtration rate in low birth weight infants during the first year of life: noninvasive 
assessment of bod y composition and growth. J Pediatr .
[ADDRESS_964812];109(4):698-707. 
  059MV0
Product:   MK-7655A 63
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential14.Schwartz GJ, Work DF. Measurement and estimation of GFR in children and 
adolescents.  Clin J Am Soc Nephrol 2009;4:1832 -43.
15.Sakellaris G, editor. Essentials in Pediatric Urolo gy. Trivandrum: Research Signpost; 
c2012. Chapter 2. The development of renal function; p. [ADDRESS_964813]:   MK-7655A 64
Protocol/Amendment No.: 020-[ADDRESS_964814] for Clinical Trials
[COMPANY_006] *
Code of Conduct for Clinical Trials
I. Introduction
A. Purpose
[COMPANY_006], through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, [COMPANY_006] clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by [CONTACT_75395] (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trials which are not under the control of [COMPANY_006].
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of [COMPANY_006] or comparator products.  Alternatively, [COMPANY_006] may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subjects must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
[COMPANY_006] selects investigati ve sites based on medical expert[INVESTIGATOR_18700], access to appropriate subjects, adequacy of facilities 
and staff, previous performance in [COMPANY_006] trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by [CONTACT_90093] t he ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  [COMPANY_006] reviews clinical data for accuracy, comple teness and c onsistency. Data are verified versus source 
documentation according to standard operating procedures.  Per [COMPANY_006] policies and procedures, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, [COMPANY_006] seeks to publish theresults of trials it conducts.  Some early phase or 
pi[INVESTIGATOR_26346] -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by [CONTACT_75397].
[COMPANY_006]’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduc t of the trial, 
performance or interpretation of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  [COMPANY_006] funding of a trial will be acknowledged in publications.  
  059MV0
Product:   MK-7655A 65
Protocol/Amendment No.: 020-[ADDRESS_964815] Prot ection
A.IRB/ERC review
All clinical trials will be reviewed and approved by [CONTACT_75398]/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by [CONTACT_1201]/ERC prior to implementation, except that 
changes required urgentl y to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and [COMPANY_006] will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are ne ver denied access to appropriate medical care 
based on participation in a [COMPANY_006] clinical trial. 
All participation in [COMPANY_006] clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a [COMPANY_006] trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
[COMPANY_006] is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by [CONTACT_2371], 
only the investigator, sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by [CONTACT_2300].  
D.Genomic Research
Genomic Research will only beconducted in accordance with informed consent and/or as specifically authorized by 
[CONTACT_75399].
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time- and labor-intensive.  It is [COMPANY_006]’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performe d in support of [COMPANY_006] trials.  [COMPANY_006] does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, additional payments ma y be made 
to compensate for the time spent in extra recruiting efforts.
[COMPANY_006] does not pay for subject referrals.  However, [COMPANY_006] may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects.
B.Clinical Rese arch Funding 
Informed consent forms will disclose that the trial is sponsored by [CONTACT_44873], and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wordi ng of the disclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from [COMPANY_006] trials will indicate [COMPANY_006] as a source of funding.
C.Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g.,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by [CONTACT_75401] (AMA). 
V. Investigator Commi tment
Investigators will be expected to review [COMPANY_006]’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "[COMPANY_006]" refers to [COMPANY_006] Sharp & Dohme Corp. and Schering Corporation, each of which is a 
subsidiary of [COMPANY_006] & Co., Inc.  [COMPANY_006] is known as MSD outside of the [LOCATION_002] and Canada.  As warranted by 
[CONTACT_74647], [COMPANY_006] also includes affiliates and subsidiaries of [COMPANY_006] & Co., Inc." 
  059MV0
Product:   MK-7655A 66
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Approximate Blood/Tissue Volumes Drawn/Collected by [CONTACT_26402], with many centers suggesting a 0.5mL blood draw for
most standard clinical tests in neonates (blood culture, hematology  with differential, and 
clinical chemistry  panels). With this recognition in mind, expected blood volumes for the 
youngest age group (neonates) are calculated below:
Trial Visit/Cycle/etc:Screening
Visits 1Treatm ent 
Visit 2Post-
Treatm ent
Visit 3Post-
Treatm ent
Visit 4
Blood Param eter Approxim ate Blood Volume
Serum β-Hum an Chorionic 
Gonadotropin (β -hCG)a0.5mL
Hem atology 0.5mL 0.5 mL 0.5 mL
Blood Chemistry 0.5 mL 0.5 mL 0.5 mL
Plasma Pharmacokinetics 1 mL
(4 × 250 µL)
Expected Total (mL) 1.5 mL 1 mL 1 mL 1 mL
a.For female subjects of child -bearing potential only.
The approximate total blood volume to be drawn is within 3% of total blood volume (2.4 mL 
blood per kg of body  weight) even for the lowest approximate weight for eligible subjects in 
this study  (ie, female neonates in the first percentile of growth according to World Health 
Organization growth charts). Maximum volume for an individual subjec t should be based on 
weight and should generally  not exceed 3% of total blood volume (2.4 mL blood per kg of 
body  weight) unless appropriate justification is documented b y the investigator. 
  059MV0
Product:   MK-7655A 67
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential
Acceptable Creatinine Clearance Range s by [CONTACT_709669]
12 to <18 years ≥80mL/min Cock croft-Gaultc
2 to <12 years ≥80 mL/min/1.73m2Modified Schwartzd
18 months to <2 years ≥76 mL/min/1.73m2Modified Schwartzd
12 to <18 months ≥73 mL/min/1.73m2Modified Schwartzd
8 to <12 months ≥65 mL/min/1.73m2Modified Schwartzd
14 weeks to <8 months ≥57 mL/min/1.73m2Modified Schwartzd
6 to <14 weeks ≥47 mL/min/1.73m2Modified Schwartzd
2 to <6 weeks ≥41 mL/min/1.73m2Modified Schwartzd
1 to <2 weeks ≥25 mL/min/1.73m2Modified Schwartzd
Birth to <1 week ≥20 mL/min/1.73m2Modified Schwartzd
a. Normal creatinine clearance ranges taken from published lower -bound standard deviation of age-appropriate means
[13, 14, 1 5].
b. Food and Drug Administration guidance recommends Cock croft-Gault formula in adolescents ≥12years of age and the 
modified Schwartz formula for infants and children <12 years of age [11].
c. Cock croft-Gault formula (subjects ≥12 years of age):
Crea tinine clearance (m ales) = (weight in kg) × (140 minus age)     
(72) × (creatinine in mg/dL)
Creatinine cl earance (f emales) = 0.85 × the value obtained using the formula above
d. Modified Schwartz formula (subjects <12 years of age):
Creatinine clearance =     K × (height in cm)___  
(creatinine in mg/dL)
K (proportionality constant):
Infant (term <1 year): K=0.45
Female child ( ≥1 year and <12 years): K=0.55
Male child ( ≥1year and <12 years): K=0.[ADDRESS_964816]:   MK-7655A 68
Protocol/Amendment No.: 020-[ADDRESS_964817] aspartate aminotransferase
AUC 0-∞ area under the concentration time curve 
β-hCG β-human chorionic gonadotropin
BLI β-lactamase inhibitor 
CEOI concentration at end of infusion
CI coordinating investigator
[INVESTIGATOR_709635] -abdominal infection
CL systemic clearance
Cmax maxim um observed plasma concentration
CMS colistimethate sodium
CSR clinical study report
cUTI complicated urinary tract infection
%CV coefficient of variation
ECI event of clinical interest
eCRF electronic case report form
EDC electronic data capture
EMA European Medicines Agency
ERC Ethical Review Committee
FDAAA Food and Drug Administration Amendments Act
GCP Good Clinical Practice
HABP hospi[INVESTIGATOR_307] -acquired bacterial pneumonia
IB Investigator’s Brochure
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IMI imipenem /cilastatin
IMI/RELfixed- dose combination of imipenem/cilastatin/relebactam 
(MK -7655A)
IMP Imipenemase metallo -β-lactamase
IRB Institutional Review Board
IV intravenous (parental)
IVRS interactive voice response system
IWRS interactive web response system
KPC Klebsiella pneumoniae carbapenemase 
LAR legally acceptable representative
M&S modeling and simulation
MDR multi -drug resistant
NCA noncompartmental analysis
NDM -[ADDRESS_964818]:   MK-7655A 69
Protocol/Amendment No.: 020-[ADDRESS_964819] in the heart ’s electrical 
cycle
REL relebactam
SAE serious adverse event
t1/[ADDRESS_964820]:   MK-7655A 70
Protocol/Amendment No.: 020-02 
MK-7655A -020-02 Final Protocol 22-AUG -2019
Confidential13.0 SIGNATURES
Sponsor's Representative
TYPED NAME
[CONTACT_26409]
I agree to conduct this clinical trial in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373] (including other manuals and documents 
referenced from this protocol).  I  agree to conduct the trial in accordance with generally 
accepted standards of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particula r, I agree to report any serious adverse events 
as defined in Section 7.0–TRIAL PROCEDURES (Assessing and Recording Adverse 
Events ).  I also agree to handle all clinical supplies provided by [CONTACT_26403].  I understand that information 
that identifies me will be used and disclosed as described in the protocol, and that such 
information may be transferred to countries that do not have laws protecting such 
information.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to any third parties, other than those 
involved in approval, supervision, or conduct of the trial is prohibited.  I will ensure that the 
necessary  precautions are taken to protect such information from loss, inadvertent disclosure 
or access b y third parties.
TYPED NAME
[CONTACT_26410] 
  059MV0